Six things to know about scalp treatment
Structured for search, voice, and AI overview extraction. These answers define the diagnosis-first frame — what scalp treatment covers, how it differs from hair regrowth, which conditions are common, and how Indian-scalp realities are integrated — before the detailed education begins.
When to consider a scalp-dermatology assessment
Patients usually arrive for scalp-dermatology assessment after months of trying over-the-counter shampoos and home routines without sustained improvement. Some arrive after a salon scalp treatment that produced temporary improvement followed by return of symptoms. Some arrive with overlapping concerns — itchy flaky scalp plus increased shedding, oily scalp plus papules, sensitive scalp plus product reactions — and want a single coordinated diagnosis-and-plan rather than chasing each symptom separately. The dermatologist welcomes all of these presentations and approaches every consultation diagnosis-first because the appropriate topical and oral therapy depends entirely on which scalp condition is actually present.
The most important sentence on this page is this: the scalp is skin, and it develops the same conditions as facial or body skin plus a few scalp-specific patterns. Marketing language at some clinics implies that scalp problems are mostly cosmetic concerns to be solved with shampoos and serums. They are not. Seborrhoeic dermatitis, scalp psoriasis, scalp eczema, fungal scalp infections, folliculitis, scalp acne, and pollution-driven scalp inflammation are real medical conditions with specific evidence-based treatments. Salon-grade treatments may produce brief improvement but do not treat the underlying condition; recurrence is the norm without medical-grade therapy.
The second important sentence is that scalp diagnosis matters. Treating seborrhoeic dermatitis with a psoriasis-targeted regimen produces little benefit; treating tinea capitis with topical anti-dandruff shampoo allows the fungal infection to spread; treating sensitive-scalp reaction by adding more products often makes the reaction worse. The dermatologist examines the scalp, performs dermoscopy where helpful, sometimes orders KOH preparation or culture, and confirms the specific condition before committing to therapy.
The third important sentence is that maintenance matters in chronic scalp conditions. Seborrhoeic dermatitis recurs in nearly all patients without ongoing maintenance. Scalp psoriasis is lifelong with flares and remissions. Scalp eczema follows the broader eczema course. Tinea capitis usually does not recur after appropriate treatment. The realistic plan addresses both acute control and long-term stability rather than promising one-time resolution.
Common reasons patients seek scalp assessment
Persistent flaking despite anti-dandruff shampoos. Itchy, red, or burning scalp with no obvious external cause. Oily scalp with greasy yellow scaling. Well-defined raised plaques with thick scaling. Dry patches that itch and crack. Patchy hair loss with scaling that suggests fungal infection. Small red papules or pustules at follicle openings. Acne-like papules along the hairline or nape. Scalp that reacts to any product introduction with stinging or redness. Scalp condition flaring during seasonal change or under stress. Hair shedding accompanying any of the above. Multiple family members with similar scalp concerns. A child with a scaly patchy area on the scalp. A previous scalp condition recurring after a period of improvement.
None of these are emergencies. They are reasons for a non-urgent dermatology consultation. The dermatologist examines, classifies the condition, may order targeted tests, and proposes a graded plan with realistic timelines and an explicit maintenance discussion.
When patients should come in promptly
Severe itch with sleep disruption. Significant impact on quality of life warrants prompt evaluation rather than prolonged self-treatment.
Rapidly spreading scalp lesions, particularly inflamed boggy patches that may indicate kerion (severe inflammatory tinea capitis). Prompt evaluation prevents permanent scarring loss.
Scalp lesions accompanied by fever, swollen lymph nodes, or systemic symptoms. May indicate infection requiring oral antibiotics or antifungals.
Scalp condition during pregnancy with severe symptoms. Pregnancy-safe treatment options need careful selection; prompt consultation supports comfort throughout pregnancy.
A child with scaly patches and broken hairs. Likely tinea capitis; oral antifungal therapy is needed and topical-only approaches typically fail.
Patient with known immunosuppression developing scalp lesions. Underlying immunology may alter both the typical presentation and the treatment selection.
New-onset severe scalp pain or pustular eruption. May indicate folliculitis decalvans, dissecting cellulitis, or other scarring inflammatory conditions that benefit from prompt anti-inflammatory therapy.
When NOT to start treatment immediately
Recent intensive scalp procedure (chemical relaxer, aggressive bleach, ozone treatment) with current irritation. Allow scalp barrier to recover for 1–2 weeks before introducing medicated topicals; otherwise irritation compounds.
Patient on isotretinoin currently. Scalp dermatitis sometimes flares during isotretinoin therapy; the dermatologist coordinates supportive care without aggressive procedural intervention until the course completes.
Pregnancy with mild stable scalp condition. Most pregnancy-compatible options are available, but defer aggressive therapy when symptoms are tolerable; reassess postpartum.
Patient with multiple new product introductions in the last 4 weeks producing symptoms. Discontinue new products and observe for 2–4 weeks; if symptoms persist after the elimination phase, then formal evaluation begins from a baseline rather than during active provocation.
Patients with unrealistic expectations of one-time resolution for chronic conditions. Expectation alignment at consultation must precede treatment commitment. The dermatologist explains the recurrence-and-maintenance reality before therapy is initiated so the patient can decide whether to commit to long-term care.
What the scalp is and how it behaves
Patients sometimes think of the scalp as a separate organ from skin. It is not. Understanding scalp anatomy and how it behaves clarifies why specific conditions develop there and how treatment works.
The scalp is a thick stratified epidermis sitting on a richly vascular dermis containing dense terminal hair follicles, sebaceous glands, sweat glands, blood vessels, lymphatics, and nerves. The scalp has approximately 100,000 hair follicles, more sebaceous glands per unit area than most other body regions, and a robust blood supply. Its barrier function is similar to facial skin but the abundance of follicles and sebaceous glands creates a different microenvironment for skin-microbiome interactions.
The scalp microbiome includes commensal bacteria (Cutibacterium acnes, Staphylococcus epidermidis, others), commensal yeasts (Malassezia species), and small populations of fungi and other organisms. Most of these are normal and contribute to scalp health. Disruption of microbial balance — often combined with barrier compromise or immune-system shift — produces several common scalp conditions including seborrhoeic dermatitis (associated with Malassezia overgrowth) and folliculitis (often Staphylococcus or Malassezia).
The scalp\u2019s sebaceous activity is high. Sebum production peaks in adolescence and gradually declines with age. Patients with high sebum production may experience oilier scalp, more visible greasiness, and predisposition to seborrhoeic dermatitis. Patients with low sebum production may experience drier scalp, more visible flaking from cleansing detergents, and predisposition to scalp eczema.
The scalp\u2019s barrier function depends on intact stratum corneum and adequate lipid composition. Aggressive cleansing with strong sulphate detergents, high-frequency hot showers, harsh chemical processes (relaxers, bleach), and friction (tight hairstyles, abrasive brushes) all compromise the barrier and predispose the scalp to inflammation and condition flares.
The scalp\u2019s nerve supply makes it sensitive to environmental and product stimuli. Sensitive-scalp reactions are common; the patient feels burning, tingling, or itching with limited visible signs. The mechanism involves both barrier disruption and neuroinflammatory pathways.
How scalp conditions develop
Most scalp conditions arise from interactions between the scalp microbiome, immune-system activity, barrier function, and environmental inputs. Patients with susceptible immune profiles (atopic, psoriatic, immunocompromised, hyperandrogenic) are more prone. Trigger events (illness, stress, weather change, new products, hair-care intensity changes) often initiate flares.
Seborrhoeic dermatitis develops in patients with high sebum production where Malassezia yeasts thrive and trigger an inflammatory response in genetically-susceptible individuals.
Scalp psoriasis develops in patients with the underlying psoriatic immune profile, often triggered by stress, infection, certain medications, or scalp injury (Koebner phenomenon).
Scalp eczema develops in patients with atopic background, often with eczema elsewhere, triggered by barrier disruption, harsh cleansers, contact allergens, or environmental dryness.
Tinea capitis develops when dermatophyte fungi reach the scalp — typically from contact with infected children, animals, or shared items. Children are most susceptible; adult cases are unusual and warrant evaluation for predisposing factors.
Folliculitis develops when bacteria or fungi colonise hair follicles, often triggered by friction, occlusion, sweating, shaving practices, or contaminated tools.
Scalp acne develops by similar mechanisms as facial acne, with sebum, follicular plugging, and bacterial colonisation as the central drivers.
Sensitive-scalp reactions develop in patients with barrier dysfunction or contact sensitivity to specific ingredients in shampoos, conditioners, or styling products.
Why scalp differs from face in clinical management
Hair coverage limits topical application. Patients can apply leave-on creams to facial skin easily; scalp applications must navigate hair coverage, leading to use of solutions, foams, gels, sprays, and shampoo formulations rather than thick creams.
Sebaceous activity is higher. Treatments that work well on dry facial skin sometimes feel too occlusive on the scalp; dermatologists choose lighter vehicles for the scalp.
Cosmetic concerns are different. Patients may wash facial skin daily; many wash hair every 2–3 days. Treatment frequency must accommodate hair-washing realities.
Cultural hair-care practices vary widely. Cultural oiling, religious head covering, hair-styling intensity, and traditional treatments all interact with medical scalp care. The dermatologist accommodates these realities rather than imposing impractical avoidance.
Visibility differs. Scalp conditions may be partly hidden by hair coverage but become highly visible at the parting line, frontal hairline, and during styling. Patients sometimes underestimate what their scalp looks like; trichoscopy reveals reality.
How scalp conditions present clinically
Different scalp conditions produce different symptom patterns. The dermatologist learns to recognise the typical clusters at consultation. This section walks through the common symptom presentations with notes on what they typically indicate.
Itch. The most common scalp symptom. Mild intermittent itch may indicate dandruff, mild seborrhoeic dermatitis, or product irritation. Severe persistent itch with sleep disruption suggests significant inflammation — moderate-to-severe seborrhoeic dermatitis, scalp psoriasis flare, or scalp eczema. Itch with visible patches, scaling, or papules narrows the differential further.
Flaking. White or yellowish flakes ranging from fine dust-like flakes (dandruff) to large scales (psoriasis). Greasy yellow flakes on red base typically indicate seborrhoeic dermatitis. Dry white flakes without redness indicate dandruff or mild scalp eczema. Thick silver scales on raised plaques indicate scalp psoriasis. Patchy scaling with broken hairs suggests tinea capitis.
Redness. Generalised redness across the scalp may indicate widespread seborrhoeic dermatitis or sensitive-scalp reaction. Localised red patches suggest psoriasis, eczema, or contact dermatitis. Bright red follicular papules suggest folliculitis. Inflammatory boggy areas suggest kerion.
Burning sensation. Often associated with sensitive-scalp reactions, scalp psoriasis flares, or contact dermatitis. May occur with limited visible signs in some patients.
Pain. Less common but significant. Painful scalp may indicate folliculitis decalvans, dissecting cellulitis, severe folliculitis, kerion, or post-procedural inflammation. Painful nodules may indicate scalp acne or pilar cysts.
Scalp odour. Some scalp conditions produce noticeable odour — severe seborrhoeic dermatitis, certain bacterial colonisations, occlusion under hair products. The odour usually resolves with treatment of the underlying condition.
Hair shedding. Often accompanies inflammatory scalp conditions. Treating the scalp condition often improves shedding. Persistent shedding despite scalp clearance may indicate an additional hair-loss pathway needing separate evaluation.
Visible hair-quality change. Hair feels rough, brittle, or weak overlying scalp inflammation. The condition affects both follicle and shaft.
Patchy hair loss with scalp scaling. In children primarily — tinea capitis. In adults — scarring alopecia (lichen planopilaris), folliculitis decalvans, or unusual conditions warranting biopsy.
Pustules. Small white-headed papules suggest folliculitis (bacterial or fungal), scalp acne, or pustular psoriasis variants. The dermatologist takes culture or KOH if uncertain.
Raised plaques. Thick silver scaling on red base — psoriasis. Greasy yellow scaling — seborrhoeic dermatitis. Hyperkeratotic bands at the hairline — sometimes called sebopsoriasis where patterns overlap.
Crusting and oozing. Rare but significant — may indicate severe inflammation, infection, or unusual pathology. Prompt evaluation.
Symptom clusters by condition
Seborrhoeic dermatitis cluster. Greasy yellow flaking, mild-to-moderate redness, itch, sometimes burning, often centred on parting line and frontal scalp; commonly extends to facial scalp areas (eyebrows, nasolabial folds, ear creases).
Scalp psoriasis cluster. Thick silver scaling on well-defined plaques, often itchy or sometimes painful, sometimes extending beyond the hairline onto forehead or behind ears; commonly with psoriasis elsewhere.
Scalp eczema cluster. Dry itchy patches, fine flaking, sometimes lichenified from chronic scratching, often with eczema elsewhere; flares with allergen or irritant exposure.
Tinea capitis cluster. Patchy hair loss with scaling, sometimes black-dot pattern, sometimes inflammatory boggy patches (kerion); primarily in children.
Folliculitis cluster. Small red papules or pustules at follicle openings, sometimes itchy, sometimes painful; often after friction, occlusion, or shaving.
Scalp acne cluster. Papules and pustules along hairline, frontal scalp, or nape; often in patients with acne-prone facial skin; aggravated by occlusive hair products.
Sensitive-scalp cluster. Burning, tingling, itch with minimal visible signs; reactions to specific products or environmental triggers.
Mixed presentations. Many patients have overlapping conditions. The dermatologist disentangles at consultation.
Why scalp conditions develop and what triggers flares
Each scalp condition has its own causal pathway. Understanding the drivers helps patients identify modifiable factors and helps the dermatologist counsel realistically about prevention and maintenance.
Driver one — genetic susceptibility. Patients with family histories of psoriasis, atopic dermatitis, or seborrhoeic dermatitis are more prone to scalp manifestations. Genetics is not destiny but it shapes susceptibility.
Driver two — sebaceous activity. High sebum production predisposes to seborrhoeic dermatitis and to scalp acne. Hormonal phases (puberty, hyperandrogenism, certain medications) modulate sebum.
Driver three — immune profile. Patients with atopic immune profile (eczema, asthma, allergic rhinitis) have scalp eczema risk. Patients with psoriatic immune profile have scalp psoriasis risk. Patients with immunosuppression have varied risks.
Driver four — barrier function. Disrupted scalp barrier from harsh cleansers, frequent hot showers, aggressive chemical processes, or friction allows entry of irritants and triggers inflammatory cascades.
Driver five — Malassezia colonisation. The commensal yeast Malassezia furfur and related species drive seborrhoeic dermatitis pathophysiology in susceptible patients. Antifungal therapy reduces yeast load and resolves inflammation.
Driver six — bacterial colonisation. Staphylococcus aureus and related bacteria colonise hair follicles and produce folliculitis, especially after friction, occlusion, or shaving.
Driver seven — fungal infection. Dermatophyte fungi cause tinea capitis after contact transmission. Predisposing factors include young age, contact with infected pets or playmates, and sometimes underlying conditions.
Driver eight — environmental factors. Climate (winter dryness, summer heat), pollution (Delhi residents face cumulative exposure), and hair-product use all influence scalp conditions.
Driver nine — stress. Stress is a documented trigger for seborrhoeic dermatitis flares, psoriasis flares, and worsening of sensitive-scalp symptoms. The mechanism involves cortisol, immune-system shifts, and behavioural changes that affect scalp care.
Driver ten — medications. Some medications affect scalp condition risk — corticosteroid withdrawal can flare seborrhoeic dermatitis; certain immunosuppressants can predispose to fungal infections; isotretinoin can produce dry-scalp dermatitis.
Driver eleven — hair-care practices. Tight hairstyles, frequent chemical processing, hot tools, occlusive styling products, and aggressive brushing all interact with scalp condition risk and severity.
Driver twelve — diet and metabolic factors. Indirect effects through inflammation. High-glycaemic-load diets and certain metabolic patterns may worsen seborrhoeic dermatitis in some patients; evidence is mixed and individual.
Common flare triggers
Seasonal change. Winter often flares seborrhoeic dermatitis, scalp eczema, and psoriasis through dryness and reduced humidity. Some patients flare in summer from heat and sweating.
Stress events. Major stressors (job change, relationship transition, illness, bereavement) often precipitate flares of chronic scalp conditions.
Illness. Systemic illness sometimes triggers seborrhoeic dermatitis or psoriasis flares.
New product introduction. Sensitive-scalp patients sometimes flare with any new product. The dermatologist counsels conservative product introduction one item at a time.
Aggressive hair processing. Bleaching, relaxers, intense colour processing on previously stable scalps can trigger sensitive-scalp reaction or flare underlying conditions.
Headwear changes. New hat use, helmet use, religious headcovering changes — friction and occlusion patterns shift and may flare folliculitis or sensitive-scalp reactions.
Sleep disruption. Chronic sleep restriction can flare chronic inflammatory conditions.
Hormonal phases. Pregnancy, postpartum, menopause, contraceptive starts and stops all interact with scalp conditions.
Pollution exposure. High-pollution days can produce scalp itch and inflammation in sensitive patients.
Contact with infected children or pets. Tinea capitis transmission.
What patients can modify
Cleansing routine. Adjust frequency and product selection to support barrier function.
Product simplicity. Reduce the number of leave-on products to identify and avoid triggers.
Hair processing intensity. Reduce frequency of aggressive chemical processes during active flares.
Stress management. Support overall scalp health.
Sleep adequacy. Support immune-mediated condition stability.
Environmental adjustments. Humidifiers in winter, head-cover for outdoor pollution exposure, gentle towel-drying instead of vigorous rubbing.
Compliance with prescribed therapy. The single largest determinant of long-term outcomes.
The scalp-dermatology assessment at DDC
A structured assessment underpins every scalp-treatment plan. The DDC consultation runs 30–45 minutes and produces a written diagnosis plus a treatment plan that addresses each contributing condition.
History. Onset, duration, progression, prior treatments and responses, family history of related conditions, recent triggers, current scalp routine, hair-care practices, occupational exposures, allergies, current medications, pregnancy status, immune-related conditions.
Visual examination. Whole-scalp inspection under good lighting. Distribution patterns matter — central scalp seborrhoeic versus localised psoriasis versus generalised eczema versus patchy fungal versus follicular folliculitis. Photographs at standardised lighting establish baseline.
Dermoscopic examination. Magnified examination of affected areas reveals features distinguishing similar-looking conditions — yellow greasy scaling versus silver scaling, follicular preservation versus follicular destruction, broken hairs versus exclamation-mark hairs, and others.
KOH preparation. Skin scrapings examined under microscope for fungal hyphae. Used when tinea capitis or fungal folliculitis is suspected. Quick same-visit result if equipment available; otherwise overnight processing.
Bacterial culture. Pus or exudate cultured for organism identification and antibiotic sensitivity. Used in suspected bacterial folliculitis not responding to first-line therapy or with concerning features.
Patch testing. For sensitive-scalp reactions where contact allergy is suspected. Series of common allergens applied to back skin and read at 48–96 hours. Identifies specific allergen for avoidance.
Scalp biopsy. Reserved for unclear or refractory cases. Small punch biopsy under local anaesthesia; healing in 7–14 days; histopathology in 7–14 days. Useful for distinguishing scarring alopecia subtypes, atypical inflammatory presentations, and rare conditions.
Hair-pull test. A gentle pull of a small tuft. Counting telogen hairs assesses active shedding. Positive pull suggests active telogen effluvium or other shedding pathology.
Laboratory tests. Selectively in patients with severe disease or systemic features. Complete blood count, ferritin, vitamin D, vitamin B12, thyroid function, and other tests as indicated.
Distinguishing clinically similar presentations
Seborrhoeic dermatitis vs scalp psoriasis. Seborrhoeic has greasy yellowish scaling on poorly defined erythema; psoriasis has thick silver scaling on well-defined plaques. Dermoscopy shows different vascular patterns. Sometimes the patient has both (sebopsoriasis).
Scalp eczema vs sensitive-scalp reaction. Eczema has visible dermatitic features (erythema, scaling, lichenification); sensitive-scalp reaction often has subjective symptoms with minimal visible signs. Patch testing distinguishes contact allergy underlying both.
Tinea capitis vs alopecia areata. Both can produce patchy hair loss in children. Tinea has scaling and broken hairs; alopecia areata has smooth bald patches with exclamation-mark hairs and yellow dots on dermoscopy. KOH or culture confirms tinea.
Folliculitis vs scalp acne. Folliculitis is purely follicular inflammation often with pustules; scalp acne includes papules and comedonal-like lesions in addition. Distribution and clinical pattern distinguish.
Scarring vs non-scarring conditions. Trichoscopy is critical. Scarring conditions (lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia, dissecting cellulitis, folliculitis decalvans) show loss of follicular openings. Non-scarring conditions preserve the follicular openings.
Documentation
The consultation record includes history, physical findings, dermoscopic features, results of any tests, working diagnosis, treatment plan, alternative options considered, patient preferences, and follow-up timing.
Patients receive a written or digital copy of the plan.
Photographs at consultation, then at 4 weeks, 8 weeks, 12 weeks during the active phase establish a longitudinal record.
Patients are encouraged to take their own home photographs at intervals to track response between clinic visits.
Why scalp dermatology has its own subspecialty considerations
Scalp dermatology shares principles with general skin dermatology but has specific considerations that warrant subspecialty attention. Vehicles for topical therapy must navigate hair coverage. Sebaceous activity is higher than most body sites. Cultural hair-care practices vary widely. Hair loss often coexists with scalp conditions and warrants coordinated care.
The dermatologist with scalp-condition experience recognises patterns that less-experienced clinicians may miss — early scarring alopecia, atypical fungal presentations, sebopsoriasis overlap, peri-follicular signs that reveal subclinical disease.
Some scalp conditions are sufficiently rare that specialist subspecialty referral provides the best care. Lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia, dissecting cellulitis, and severe folliculitis decalvans benefit from coordinated specialist care.
Most patients with common conditions (seborrhoeic dermatitis, scalp psoriasis, scalp eczema, scalp acne, sensitive scalp) are well-managed in general dermatology with appropriate diagnostic care. Specialist referral is reserved for refractory or unusual presentations.
Trichoscopy as a foundational tool
Trichoscopy is the magnified examination of the scalp using a dermoscope at 10x magnification. The technique reveals features the naked eye cannot see and is foundational to modern scalp dermatology.
Healthy scalp trichoscopy. Visible follicular openings; mixed thick and thin hairs (some natural variation); evenly distributed pigmentation around follicles.
Seborrhoeic dermatitis trichoscopy. Yellow scaling on follicular openings; sometimes serpentine vessels; usually preserved follicular structures.
Scalp psoriasis trichoscopy. Silver-white scaling; characteristic vascular pattern (red dots, glomerular vessels); preserved follicular structures.
Scalp eczema trichoscopy. Mild scaling without specific characteristic features; vascular pattern often less prominent than psoriasis; follicular structures preserved.
Tinea capitis trichoscopy. Comma hairs, corkscrew hairs, broken hairs at varying lengths, sometimes black dots from broken hairs at the surface.
Alopecia areata trichoscopy. Yellow dots, black dots, exclamation-mark hairs (tapered toward the scalp), short vellus hairs.
Scarring alopecia trichoscopy. Loss of follicular openings — the key sign distinguishing scarring from non-scarring patterns. Sometimes peri-follicular scaling, white patches, or perifollicular pigmentary changes.
Folliculitis trichoscopy. Pustules at follicular openings; sometimes peri-follicular scaling; sometimes broken hairs.
Trichoscopy training. Different dermatologists have varying levels of trichoscopy expertise. Senior dermatologists at DDC have specific trichoscopy training; trichoscopy is performed at every scalp consultation where helpful.
Photography and longitudinal tracking
Standardised photographs at consistent lighting and head position provide longitudinal tracking. Most patients are surprised at how much their scalp condition has improved when they see baseline photos at the 12-week review.
Patient self-tracking. Smartphone photos at home in consistent lighting at 4-week intervals support patient awareness of progress. The dermatologist provides specific guidance on photo angles and lighting for self-tracking.
Photo review at clinic visits. Side-by-side comparison of baseline and current photos helps the patient and dermatologist agree on response.
Long-term photographic record. Patients on long-term care benefit from accumulated photographic record across years. Some patients have records spanning a decade documenting stable maintenance.
Common scalp conditions covered in this pathway
Comprehensive scalp dermatology covers a defined set of common conditions. The dermatologist treats each according to its specific evidence base. This section briefly catalogues the conditions covered before deeper sections walk through each.
Seborrhoeic dermatitis. The most common scalp condition. Yeast-driven inflammatory pattern. Treatment: antifungal shampoos plus topical anti-inflammatory therapy. Long-term maintenance.
Dandruff. The milder end of the seborrhoeic spectrum. Over-the-counter anti-dandruff shampoos for many patients; prescription therapy for moderate cases.
Scalp psoriasis. Immune-mediated chronic inflammation with thick silver scaling. Topical steroid solutions or foams, vitamin D analogues, salicylic acid for descaling, plus systemic therapy in severe cases.
Scalp eczema. Atopic dermatitis affecting the scalp. Gentle non-stripping cleansing, topical steroid foams during flares, topical calcineurin inhibitors, moisturising routine, trigger avoidance.
Tinea capitis. Fungal scalp infection — primarily children, occasionally adults. Oral antifungal therapy for 6–8 weeks; topical-only is generally inadequate; family contact screening.
Folliculitis. Bacterial, fungal, or irritation-related follicle inflammation. Topical or oral antibiotic for bacterial; antifungal for Malassezia folliculitis; trigger removal for irritation type.
Scalp acne. Acne pattern affecting hair-bearing scalp. Topical retinoid solutions, salicylic acid shampoos, occasionally oral antibiotics or oral acne therapy.
Sensitive scalp. Symptomatic scalp reactions to products or triggers with minimal visible signs. Trigger identification, routine simplification, barrier support.
Pollution-driven scalp inflammation. Diffuse mild scalp irritation in chronic-pollution exposure. Gentle cleansing, antioxidant scalp serums, addressing underlying conditions.
Cradle cap. Infantile seborrhoeic dermatitis. Gentle care; usually self-limiting.
Pityriasis amiantacea. Thick adherent scaling at hairline; often associated with psoriasis or eczema. Salicylic acid descaling plus underlying-condition treatment.
Trichodynia. Painful scalp without visible inflammation. Sometimes associated with telogen effluvium or sensitive-scalp baseline. Supportive care.
Lichen planopilaris and frontal fibrosing alopecia. Scarring inflammatory conditions producing permanent hair loss. Anti-inflammatory therapy to halt progression. Coordinated with hair-loss management.
Folliculitis decalvans and dissecting cellulitis. Severe scarring inflammatory conditions of the scalp. Systemic therapy often needed; specialist supervision.
Central centrifugal cicatricial alopecia. Crown-centred scarring pattern more common in patients with type IV–VI hair textures and certain hair-care histories. Anti-inflammatory therapy plus scalp-care modification.
Conditions that need specialist or coordinated care
Severe scarring alopecia patterns. Lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia, dissecting cellulitis. Anti-inflammatory therapy to halt progression; transplant evaluation in stable late disease. Coordinated with the broader hair-loss-treatment pathway.
Severe psoriasis with extensive body involvement. Systemic therapy often needed; coordinated dermatology care across the body and scalp.
Severe atopic dermatitis with extensive eczema. Systemic therapy considerations; coordinated care.
Suspected lupus, dermatomyositis, or other autoimmune scalp involvement. Specialist evaluation and serology.
Persistent or unusual presentations not fitting common patterns. Scalp biopsy and broader diagnostic workup.
Seborrhoeic dermatitis — the most common scalp condition
Seborrhoeic dermatitis is the most common scalp condition seen in dermatology practice. This section covers its presentation, diagnosis, treatment, and long-term management.
Presentation. Greasy yellow flaking on a red base, often centred on the parting line, frontal scalp, and crown. May extend to facial scalp areas (eyebrows, nasolabial folds, beard area, ear creases) in patients with broader seborrhoeic distribution. Itch is common; burning sometimes occurs. Severity ranges from mild dandruff with non-inflammatory white flakes to severe inflammatory disease with thick yellowish crusting.
Pathophysiology. Inflammatory response to Malassezia yeasts in genetically-susceptible individuals with sufficient sebaceous activity. Multiple cofactors modulate severity — climate, stress, sebum production, immune status, certain medications.
Diagnosis. Clinical pattern recognition supported by dermoscopy. KOH preparation occasionally to confirm yeast and exclude tinea. Biopsy rare. Distinction from psoriasis is the most common diagnostic challenge.
First-line treatment. Antifungal shampoo — ketoconazole 2% applied 2–3 times weekly during active flares, then once weekly for maintenance. Alternatives include ciclopirox shampoo, zinc pyrithione, selenium sulphide. Mid-potency topical steroid solution, foam, or shampoo for flare control over 2–4 weeks. Patients are taught to apply shampoo and leave on the scalp for 5–10 minutes before rinsing.
Second-line and adjunct therapy. Topical calcineurin inhibitors (tacrolimus 0.1% or pimecrolimus 1%) for sensitive areas. Salicylic acid 2–6% in shampoo or topical solution for descaling. Tar-based shampoos in some patients. Oral antifungal therapy in severe widespread disease (rarely needed for isolated scalp seborrhoeic).
Maintenance. Antifungal shampoo once or twice weekly long-term. Many patients maintain control indefinitely with this routine. Reactive escalation during flares — increasing antifungal frequency or adding short courses of topical steroid.
Lifestyle and trigger management. Stress management. Avoidance of identified product triggers. Pollution-mitigation strategies for Delhi residents. Adequate sleep. Address concurrent conditions (anxiety, certain medication effects).
Pregnancy considerations. Ketoconazole 2% shampoo is generally considered safe with limited absorption. Mid-potency topical steroids on small areas for short courses are generally acceptable. Topical calcineurin inhibitors used selectively. The dermatologist confirms pregnancy-safe protocols.
Common patient questions about seborrhoeic dermatitis
"Will it go away?" The flares can be controlled but the underlying tendency persists. Most patients have a chronic-with-flares pattern requiring long-term maintenance.
"Is it hygiene-related?" No. Seborrhoeic dermatitis is not caused by poor hygiene. Frequency of washing is part of the management plan but the condition itself is not a hygiene issue.
"Is it contagious?" No. The Malassezia yeast that contributes to seborrhoeic dermatitis lives on most healthy adults\u2019 skin without causing disease.
"Will it spread to my children?" The genetic tendency may be inherited but the condition is not transmitted.
"What about specific scalp products marketed as anti-dandruff?" Most over-the-counter anti-dandruff shampoos contain mild active ingredients useful for mild dandruff but generally inadequate for moderate-to-severe seborrhoeic dermatitis. Patients are welcome to use what they have but the dermatologist may recommend prescription-grade alternatives for better response.
"Can I use my regular shampoo between medicated shampoo days?" Yes. Most patients alternate medicated shampoo with their regular shampoo. The medicated shampoo days carry the therapeutic effect; the regular shampoo days provide cosmetic care.
"How long should the medicated shampoo stay on the scalp?" 5–10 minutes for ketoconazole 2%. Apply to wet scalp; leave; rinse. Patients who rinse immediately reduce the therapeutic effect substantially.
"Do I need to massage the medicated shampoo into the scalp?" Gentle distribution and rubbing into the scalp surface is appropriate. Aggressive scrubbing can worsen sensitive scalp.
"What if I forget a dose?" Single missed days rarely matter for a chronic-condition maintenance regimen. Resume the next scheduled application. Patients sometimes worry unnecessarily about minor lapses.
"Should I avoid all hair products during flares?" Generally use simpler products during flares but complete avoidance is rarely necessary. Continue daily essentials with simpler formulations; pause optional styling products if convenient.
"Will I need this forever?" Most patients require ongoing maintenance therapy to prevent recurrence. The intensity of maintenance can decrease over time as the routine stabilises the condition.
"Why does it flare in winter?" Cold dry air, indoor heating, and reduced UV exposure all contribute to winter seborrhoeic flares. Treatment is intensified pre-emptively in known winter-flarers.
Patient counselling about long-term seborrhoeic management
The conversation about long-term seborrhoeic dermatitis management is structured. Patients accept that the condition is chronic; the focus shifts to manageable maintenance rather than seeking elimination. The maintenance routine — typically a medicated shampoo once or twice weekly — is sustainable for nearly all patients indefinitely.
Common patient concerns about long-term medicated shampoo use. Patients sometimes worry about long-term safety of weekly antifungal shampoo. The evidence base is reassuring; ketoconazole 2% has been used for decades with no significant long-term safety concerns identified. Routine surveillance is generally not needed; patients with unusual symptoms or concerns are evaluated.
Tolerance development. Some patients on long-term antifungal shampoo report apparent tolerance — gradual return of symptoms despite continued use. Rotation between two anti-yeast active classes (ketoconazole / ciclopirox / zinc pyrithione / selenium sulphide) often restores response. The dermatologist customises rotation strategies.
Why control is the realistic goal rather than elimination. The Malassezia yeast that contributes to seborrhoeic dermatitis is part of the normal skin microbiome. It cannot be permanently eliminated and would not be desirable to eliminate even if possible. The realistic strategy is reducing yeast load to a level the patient\u2019s skin tolerates without inflammation.
Treatment intensity by severity. Patients with mild seborrhoeic dermatitis often manage well with weekly antifungal shampoo alone. Moderate cases benefit from twice-weekly antifungal plus reactive steroid. Severe cases may need ongoing topical regimens with periodic intensification.
Why patients sometimes feel the condition is worsening despite treatment. Subjective perception varies day to day with weather, sleep, stress, hairstyle, and unrelated factors. Photographic comparison with baseline often reassures that the underlying condition is stable even when the patient feels it is getting worse on a particular day.
Scalp psoriasis — chronic inflammatory plaques
Scalp psoriasis is the scalp manifestation of psoriasis, an immune-mediated chronic inflammatory skin condition. This section covers presentation, diagnosis, and graded treatment.
Presentation. Well-defined raised plaques with thick silver scaling. May be limited to small patches or extensive across the scalp. Often itchy or sometimes painful. Plaques may extend beyond the hairline onto forehead, behind ears, or into the nape. Many patients have psoriasis elsewhere on the body.
Pathophysiology. T-cell-mediated immune activation produces accelerated keratinocyte turnover, characteristic plaques, and chronic inflammation. Triggers include stress, infection, certain medications, smoking, and scalp injury (Koebner phenomenon).
Diagnosis. Clinical pattern recognition supported by dermoscopy. Sometimes clinical examination of body skin for additional psoriasis findings. Biopsy in unclear cases. Distinction from severe seborrhoeic dermatitis is the most common diagnostic challenge.
First-line treatment. Topical corticosteroid solutions, foams, gels, or shampoos applied to affected areas. Mid-to-high potency for flare control over 2–4 weeks; lower potency or alternate-day for maintenance. Vitamin D analogues (calcipotriol) often combined with steroid for synergy. Salicylic acid 2–6% for descaling thick plaques.
Second-line and adjunct therapy. Tar-based shampoos and topical solutions. Topical calcineurin inhibitors. Phototherapy (excimer laser, UVB) for extensive scalp psoriasis. Oral therapy in severe extensive psoriasis (methotrexate, acitretin, apremilast). Biologic therapy in severe disease (anti-TNF, anti-IL-17, anti-IL-23) under specialist supervision.
Maintenance. Often combination of weekly antifungal shampoo for adjunct effect, plus reactive topical steroid or vitamin D analogue during flares. Some patients maintain stable scalp with minimal active therapy; others need ongoing regimens.
Lifestyle and trigger management. Stress management. Smoking cessation. Alcohol moderation. Avoidance of scalp trauma. Recognition of medication triggers (certain antihypertensives, lithium, antimalarials may worsen psoriasis).
Pregnancy considerations. Many topical psoriasis treatments are pregnancy-acceptable in selective use. Vitamin D analogues sparingly. Topical steroids in moderation. Systemic therapies generally avoided. Coordinated dermatology and obstetric care.
Common patient questions about scalp psoriasis
"Why do I have psoriasis?" Genetic predisposition combined with environmental triggers. Family history is positive in many patients.
"Will it spread?" Psoriasis is not contagious. Plaques may extend gradually but do not transmit to others.
"Will my hair fall out?" Active scalp psoriasis can produce some shedding from inflammation. Permanent hair loss is uncommon unless very long-standing severe disease.
"Can it be eliminated?" Treatment controls flares but does not eliminate the underlying immune predisposition. Many patients achieve long periods of stable scalp with maintenance.
"Should I avoid certain shampoos?" Some patients find specific shampoos worsen flares. The dermatologist helps identify triggers and recommend stable products.
"Will my children get it?" Genetic component exists; risk is higher than general population but not certain. SPF discipline and barrier-supportive practices for children may modulate.
Detailed counselling about scalp psoriasis trigger management
Stress as a trigger. Most patients with scalp psoriasis report flares during high-stress periods. Stress-management strategies are part of comprehensive care — adequate sleep, exercise, social support, sometimes professional counselling. The dermatologist accepts stress as a real factor while providing specific dermatology care.
Infection as a trigger. Streptococcal pharyngitis (strep throat) is a documented trigger for guttate psoriasis flares; sometimes triggers scalp psoriasis flares as well. Treatment of acute infection plus dermatology supportive care.
Medication triggers. Beta-blockers, lithium, antimalarials, certain NSAIDs, and others can trigger or worsen psoriasis. Medication review at consultation; coordination with prescribing physicians for alternatives where feasible.
Smoking. Strong association with psoriasis severity. Cessation supports better long-term outcomes.
Alcohol. Heavy use associates with psoriasis flares. Moderation recommended in patients with active disease.
Scalp injury (Koebner phenomenon). Psoriasis plaques can develop at sites of skin injury. Aggressive chemical processing on inflamed scalp can trigger new plaques. Avoid trauma during active disease.
Detailed counselling about scalp eczema barrier support
Barrier function in scalp eczema is fundamentally compromised. Restoration of barrier function is the core of long-term care.
Cleansing technique. Lukewarm water rather than hot. Brief showering. Mild non-stripping cleanser. Pat dry rather than vigorous rubbing.
Moisturising routine. Light non-greasy formulations. Apply to damp scalp where feasible to lock in moisture. Sometimes leave-in conditioners in patients tolerating them.
Active therapy timing. Topical steroid foam during flares for 1–2 weeks. Topical calcineurin inhibitor 2–3 times weekly for steroid-sparing maintenance. Reactive flare management rather than continuous active therapy.
Trigger avoidance. The most important long-term strategy. Identified contact allergens avoided indefinitely. Identified irritants minimised.
Climate adaptations. Winter dryness flares many patients. Humidifier use; heavier moisturising routine; pre-emptive use of barrier-supportive products before extreme cold. Summer sweat-related flares — gentle prompt washing after sweating; lighter formulations.
Stress as a trigger. Common in scalp eczema. Stress management as supportive intervention.
Hormonal phases. Menstrual-cycle, pregnancy, perimenopausal flares are common. Anticipated and managed reactively.
Long-term outlook. Scalp eczema is part of the broader atopic dermatitis spectrum. Most adult patients achieve stable control with consistent simple routine and trigger avoidance. Severe persistent disease may require systemic therapy.
Scalp psoriasis is a lifelong condition. Patients accept this reality at consultation; the focus shifts to manageable control. Many patients achieve long periods of stable scalp with maintenance routines.
Trigger identification. Common triggers — stress, infection, alcohol, smoking, certain medications, scalp injury. Patients learn to recognise their own triggers and adjust pre-emptively.
Topical regimen choices. The mainstay is topical corticosteroid plus vitamin D analogue. Combination products with both ingredients in a single formulation simplify the routine and improve adherence.
Descaling for thick plaques. Salicylic acid 2–6% solutions or shampoos remove thick scaling so subsequent topical therapy can penetrate. Used periodically rather than daily long-term.
Tar-based shampoos. Long-established efficacy. Some patients dislike the smell or the staining of light-coloured hair; reformulations have improved cosmetic acceptability.
Phototherapy options. Excimer laser delivers targeted UVB to localised plaques in patients with limited disease. Broader UVB sessions in patients with extensive scalp involvement plus body psoriasis. Twice or thrice-weekly sessions over 8–16 weeks.
Systemic therapy considerations. Patients with severe scalp psoriasis or extensive body psoriasis may benefit from oral systemic therapy (methotrexate, cyclosporine, apremilast) or biologics (anti-TNF, anti-IL-17, anti-IL-23). Specialist supervision; significant cost considerations; pre-prescription evaluation.
Coordination with body psoriasis. Most patients with scalp psoriasis have psoriasis elsewhere on the body. Coordinated dermatology care addresses both. Patients sometimes have scalp as the only obvious manifestation; surveillance for body involvement at follow-up visits.
Pregnancy considerations. Many psoriasis treatments are pregnancy-acceptable in selective use. Some systemic therapies are avoided. Coordinated dermatology and obstetric care.
Patient counselling about long-term scalp eczema management
Scalp eczema is part of the broader atopic dermatitis spectrum. Patients with childhood eczema sometimes have scalp involvement; some develop adult-onset scalp eczema.
Trigger identification and avoidance. Contact allergens (fragrance, PPD in dyes, methylisothiazolinone preservatives, propylene glycol), irritants (harsh sulphate detergents, hot water, friction), environmental factors (cold dry air, sweating), and stress all contribute. Patch testing identifies specific allergens.
Routine simplification. Many scalp eczema patients do best with 3–4 trusted products rather than complex routines.
Topical regimen. Mid-potency steroid foam during flares; topical calcineurin inhibitor for steroid-sparing maintenance; gentle moisturising routine.
Systemic therapy in severe cases. Severe atopic dermatitis with significant scalp involvement may benefit from dupilumab or other biologics. Specialist supervision.
Pregnancy considerations. Most topical treatments compatible. Systemic therapy reviewed individually.
Scalp eczema — atopic dermatitis affecting the scalp
Scalp eczema is the scalp manifestation of atopic dermatitis. This section covers presentation, diagnosis, and management.
Presentation. Dry itchy patches with mild fine flaking. Often less well-defined than psoriasis plaques. Lichenification (thickened skin) from chronic scratching may develop. Many patients have history of eczema elsewhere — flexural, hand, periocular.
Pathophysiology. Atopic immune profile combined with barrier dysfunction. Triggers include irritant exposures (harsh shampoos, hot water, friction), contact allergens, environmental dryness, sweating, stress.
Diagnosis. Clinical pattern with patient history of atopic background. Patch testing in patients with suspected contact allergy. Sometimes biopsy in unusual presentations.
First-line treatment. Gentle non-stripping cleansing routine. Mid-potency topical steroid foam or solution during flares for 2–4 weeks. Topical calcineurin inhibitors as steroid-sparing maintenance. Moisturising routine — fragrance-free conditioner, gentle leave-on cream where tolerated. Identification and avoidance of contact triggers.
Second-line and adjunct therapy. Wet-wrap therapy for severe localised flares. Phototherapy in severe scalp eczema. Systemic therapy (oral immunomodulators, biologics) in severe extensive atopic dermatitis with scalp involvement.
Maintenance. Gentle cleansing and moisturising routine indefinitely. Topical calcineurin inhibitor 2–3 times weekly for maintenance. Trigger avoidance. Reactive flare management.
Lifestyle and trigger management. Avoid harsh sulphate detergents. Use lukewarm water; avoid hot showers. Pat dry rather than vigorous towel-rubbing. Avoid wool and rough textile contact at the scalp. Manage stress. Identify food triggers if specific ones are individually relevant; routine elimination diets are not generally helpful.
Pregnancy considerations. Most treatments compatible with pregnancy in selective use. Topical steroids in moderation; topical calcineurin inhibitors generally acceptable; systemic therapy reviewed individually.
Common patient questions about scalp eczema
"Why do I have it?" Atopic immune profile combined with barrier susceptibility. Family history of atopic conditions is common.
"Is it contagious?" No.
"Will it always come back?" The underlying tendency persists. Maintenance routine reduces flare frequency and severity.
"Are products causing it?" Sometimes yes — specific contact allergens or irritants in shampoos or styling products. Patch testing identifies individual triggers.
"Can stress make it worse?" Yes. Stress is a documented flare trigger.
"Will my child grow out of it?" Many children with atopic dermatitis improve significantly through adolescence. Adult relapses occur in some.
Detailed eczema-trigger management
Common environmental triggers. Cold dry air with low humidity; aggressive heating; harsh sulphate detergents; hot water; vigorous towel-rubbing; abrasive brushes and combs; rough textile contact.
Common product triggers. Fragrance — the most common scalp eczema allergen. Methylisothiazolinone (MI) and methylchloroisothiazolinone (MCI) — preservatives in many shampoos. Cocamidopropyl betaine — surfactant. Quaternium-15 and other formaldehyde-releasers. Specific botanical extracts in some patients.
Common dietary triggers. Generally not strong contributors in adult scalp eczema. Some patients with severe atopic dermatitis identify specific food triggers; routine elimination diets are generally not helpful.
Trigger identification approach. Diary keeping for 2–4 weeks recording flares, products used, environmental conditions, stress events, dietary patterns. Patterns often emerge that the patient had not recognised.
Patch testing for contact allergens. Standard series plus expanded panels including hair-product allergens. Specific allergens identified for indefinite avoidance.
Avoidance strategies. Once specific triggers are identified, simple avoidance often produces substantial improvement. The dermatologist provides written allergen-avoidance guidance plus a list of acceptable products.
Detailed scalp-acne severity grading
Mild scalp acne. Few papules, no pustules, mild distribution. Topical therapy alone usually adequate. Trigger management often resolves.
Moderate scalp acne. Multiple papules and some pustules. Topical regimen plus periodic oral antibiotic in some cases.
Severe scalp acne. Extensive papules and pustules, sometimes nodules, scarring potential. Oral antibiotic mainstay; oral isotretinoin in selected cases.
Nodulocystic scalp acne. Deep nodular lesions. Aggressive treatment to prevent permanent scarring loss. Oral isotretinoin often appropriate.
Folliculitis-decalvans-overlap scalp acne. Some patients develop scarring inflammatory pattern that combines features of severe scalp acne and folliculitis decalvans. Specialist treatment with combination antibacterial and anti-inflammatory therapy.
Fungal scalp infections — tinea capitis and Malassezia folliculitis
Fungal scalp infections include dermatophyte tinea capitis (primarily children) and Malassezia folliculitis (adults and adolescents). This section covers both.
Tinea capitis presentation. Patchy hair loss with scaling, often black-dot pattern from broken hairs at the surface, sometimes inflammatory boggy patches called kerion. Predominantly in children aged 3–10. Adult tinea capitis is unusual and warrants evaluation for predisposing factors. Highly contagious through shared combs, hats, pillows, and direct contact.
Tinea capitis diagnosis. KOH preparation showing fungal hyphae plus fungal culture identifying species. Wood\u2019s lamp examination shows green fluorescence with some species (Microsporum) but not all (Trichophyton). Histopathology occasionally.
Tinea capitis treatment. Oral antifungal therapy is required; topical alone is inadequate. Terbinafine 250 mg daily for 4–6 weeks (children at weight-adjusted doses) for most species; griseofulvin for species where terbinafine is less active. Adjunct selenium sulphide or ketoconazole shampoo to reduce shedding of spores during therapy. Family member screening. Treatment of any contact-source pet.
Tinea capitis follow-up. Re-evaluation at 4–6 weeks; KOH and culture to confirm clearance. Some species respond more slowly than others. Recurrence after appropriate treatment is unusual.
Kerion management. Severe inflammatory tinea capitis presenting as boggy painful inflamed patches. Oral antifungal as primary therapy plus brief course of oral corticosteroid in some cases to reduce inflammation and prevent scarring loss. Prompt treatment is important for permanent-loss prevention.
Malassezia folliculitis presentation. Small itchy follicular papules and pustules on the scalp, upper back, chest, and shoulders in adolescents and adults. Often after sweating, occlusive clothing, or prolonged antibiotic courses that disrupt the bacterial microbiome and allow Malassezia overgrowth.
Malassezia folliculitis diagnosis. Clinical pattern; KOH showing yeast forms in the follicles; sometimes biopsy in atypical cases.
Malassezia folliculitis treatment. Topical antifungal (ketoconazole 2% shampoo, ciclopirox) plus oral antifungal in moderate-to-severe cases (oral itraconazole or fluconazole for 2–4 weeks). Avoidance of occlusive clothing or styling products during the active phase.
Common patient questions about fungal scalp infections
"How did I catch it?" Tinea capitis from infected children, animals, or shared items. Malassezia folliculitis from internal microbiome shifts often after sweating, antibiotics, or occlusion.
"How long will treatment take?" Tinea capitis 4–8 weeks oral therapy. Malassezia folliculitis 2–4 weeks oral therapy plus topical maintenance.
"Will it scar?" Most non-inflammatory tinea capitis does not scar. Severe inflammatory kerion can produce scarring loss; early treatment minimises this.
"Can my children spread it to me?" Tinea capitis is contagious; reasonable precautions during the family treatment period reduce transmission. Adult-to-adult transmission is less common than child-to-adult.
"Will the hair grow back?" Yes in most non-scarring cases over 3–9 months after fungal clearance. Scarring kerion may produce permanent loss in affected zones.
Detailed paediatric tinea capitis management
Tinea capitis is the most common scalp condition needing specific dermatology care in children. Most cases are uncomplicated and respond well to oral antifungal therapy combined with adjunct topical care and family-screening.
Initial evaluation. KOH preparation usually positive. Fungal culture identifies species and guides specific antifungal selection. Wood\u2019s lamp examination shows green fluorescence with some Microsporum species; not all dermatophytes fluoresce. Photographs document baseline.
Family screening. Siblings and close household contacts often have asymptomatic colonisation. Examination of all household members supports identification of the index source and treatment of any other affected family members. Pet examination if relevant.
Oral terbinafine. Weight-adjusted dosing — typically 62.5 mg daily for children 10–20 kg, 125 mg daily for 20–40 kg, 250 mg daily for over 40 kg. Course typically 4–6 weeks for most species; longer for some Microsporum. Liver-function review before extended courses.
Oral griseofulvin. Older first-line agent. Better activity against some Microsporum species. Course 6–8 weeks. Liver-function review.
Oral fluconazole or itraconazole. Used in selected cases based on species and tolerability.
Topical adjunct. Selenium sulphide shampoo or ketoconazole 2% shampoo used 2–3 times weekly during the oral antifungal course to reduce fungal-spore shedding and reduce family transmission risk.
Hair removal of broken-hair stubble. Sometimes brief shaving or trimming of affected zones to reduce fungal load and improve topical penetration. Not necessary in all cases.
Environmental decontamination. Hot-wash shared bedding, towels, hats. Replace combs and brushes if they cannot be properly disinfected. Disinfect any shared items.
School and social settings. Children with tinea capitis typically can attend school during treatment with reasonable precautions — covered hair, no shared headwear, no shared brushes. Specific school policies vary; the clinic provides written guidance for school authorities if needed.
Re-evaluation at completion of oral course. KOH preparation and culture confirm clearance. Some species respond more slowly; extended courses sometimes needed.
Hair regrowth phase. After fungal clearance, hair regrows over 3–9 months in most cases. Severe inflammatory kerion may produce scarring loss in affected zones.
Detailed kerion management
Kerion is severe inflammatory tinea capitis with boggy painful inflamed patches. Prompt treatment is important to prevent permanent scarring loss.
Recognition. Boggy painful tender patches with pustules; sometimes draining purulent material; lymphadenopathy. Often misdiagnosed as bacterial infection.
Diagnosis. KOH preparation and culture. Sometimes bacterial culture also (secondary bacterial infection can coexist).
Treatment. Oral antifungal as primary therapy. Brief course of oral corticosteroid (prednisolone 0.5–1 mg/kg for 1–2 weeks tapered) in some cases to reduce inflammation. Topical antifungal as adjunct. Sometimes oral antibiotic if bacterial superinfection suspected.
Outcome. Most cases resolve with appropriate treatment over 6–10 weeks. Permanent hair loss in severely affected zones in some patients.
Folliculitis — bacterial, fungal, or irritant inflammation of hair follicles
Folliculitis is inflammation of hair follicles producing follicular papules and pustules. This section covers the common types and their management.
Bacterial folliculitis. Most commonly Staphylococcus aureus. Presents as small red papules or pustules at follicle openings, often itchy or tender. Triggers include friction (helmets, hats), occlusion (sweating under headcovering), shaving, and contaminated tools. Diagnosis usually clinical; culture in refractory cases.
Bacterial folliculitis treatment. Topical antibiotic (mupirocin, fusidic acid, clindamycin) for limited disease. Oral antibiotic (cephalexin, dicloxacillin, clindamycin, doxycycline) for extensive or refractory disease for 7–14 days. Trigger removal — adjust friction sources, change tools, address shaving practices. Antibacterial shampoo (chlorhexidine, povidone-iodine) for ongoing colonisation control.
Malassezia folliculitis. Yeast-driven follicular inflammation. Discussed in the fungal-infections section. Often misdiagnosed as bacterial folliculitis when antifungal therapy would be more appropriate.
Pseudomonas folliculitis. From contaminated water (hot tub, pool). Presents 8–48 hours after exposure with widespread follicular pustules. Usually self-limiting. Hygiene of source water addresses recurrence.
Eosinophilic folliculitis. Rare; sometimes seen in immunocompromised patients. Specialist evaluation.
Pseudo-folliculitis (razor bumps). From shaving with curved hair re-entering skin. Common in men with curly hair and patients with religious shaving practices. Adjust shaving technique; consider laser hair reduction in selected cases.
Folliculitis decalvans. Severe scarring inflammatory folliculitis with progressive follicular destruction and tufted hairs (multiple hairs from single follicle). Specialist treatment with anti-inflammatory and antibacterial therapy; topical and oral.
Dissecting cellulitis of the scalp. Severe scarring inflammatory condition with deep boggy painful nodules and sinus-tract formation. Specialist treatment with isotretinoin, biologics, or surgical drainage in selected cases.
Common patient questions about folliculitis
"Why do I get folliculitis?" Multifactorial — friction, occlusion, sweating, shaving, contaminated tools, microbiome shifts. Identifying contributing factors helps prevention.
"Is it contagious?" Bacterial folliculitis can transmit on shared towels and razors but is not highly contagious. Reasonable precautions reduce risk.
"Will it scar?" Mild folliculitis usually does not scar. Severe or chronic folliculitis can produce scarring loss; early appropriate treatment minimises.
"Can I exercise?" Yes. Reduce friction over affected areas during recovery (modify headwear or hairstyles). Shower promptly after sweating.
"Will it come back?" Possible, especially in patients with contributing factors that persist. Maintenance prevention strategies reduce recurrence.
Detailed folliculitis management by type
Bacterial folliculitis. Most commonly Staphylococcus aureus. Topical antibiotic for limited disease — mupirocin 2% cream three times daily to affected areas for 7–14 days, or fusidic acid 2% cream similarly, or clindamycin 1% solution twice daily. Oral antibiotic for extensive disease — cephalexin, dicloxacillin, doxycycline, or clindamycin for 7–14 days. Decolonisation strategy in recurrent disease (mupirocin nasal application; chlorhexidine body wash).
Pseudo-folliculitis (razor bumps). From shaving with curved hair re-entering skin at the follicle exit. Common in men with curly hair; common in patients with religious or occupational shaving practices. Adjust shaving technique — shave in direction of hair growth; use single-blade or electric razor; avoid close shaving. Topical retinoid in some patients to support follicular release. Laser hair reduction in selected cases produces durable improvement.
Recurrent folliculitis with carrier-state colonisation. Some patients have nasal Staphylococcus aureus colonisation that re-seeds folliculitis after each treatment. Decolonisation regimen — mupirocin nasal twice daily for 5 days plus chlorhexidine body wash daily for 5 days. Repeat as needed. Family-member decolonisation if relevant.
Folliculitis decalvans. Severe scarring inflammatory folliculitis with progressive follicular destruction and tufted hairs. Specialist treatment with anti-inflammatory and antibacterial therapy. Topical fusidic acid plus oral rifampicin and clindamycin combination is one well-known regimen. Topical and intralesional corticosteroids during flares. Long-term follow-up required.
Dissecting cellulitis of the scalp. Severe scarring inflammatory condition with deep boggy painful nodules and sinus-tract formation. Often associated with hidradenitis suppurativa elsewhere on the body. Specialist treatment with isotretinoin (extended courses), biologics (anti-TNF), or surgical drainage in selected cases.
Eosinophilic folliculitis. Rare; sometimes seen in immunocompromised patients. Specialist evaluation and treatment.
Pseudomonas folliculitis. From contaminated water (hot tub, pool). Self-limiting in healthy patients over 2–3 weeks. Hygiene of source water for recurrence prevention. Antibiotic therapy in immunocompromised patients or severe disease.
Detailed scalp acne distinct from facial acne
Hairline distribution. Scalp acne often concentrates along the frontal hairline and temple region in patients who use occlusive hair products applied to that zone. Treatment includes product modification.
Crown distribution. Patients who wear caps, helmets, or other crown-pressure headwear sometimes develop crown acne. Adjust pressure and humidity at the headwear site.
Nape distribution. Patients with hair products draining to the nape during washing or styling can develop nape acne. Adjust product application technique.
Combined facial and scalp acne. Coordinated approach with shared topical actives (retinoid, salicylic acid) used at appropriate concentrations for each area.
Scarring concerns. Severe nodular scalp acne can produce permanent loss in affected zones. Aggressive treatment of severe disease prevents long-term cosmetic damage.
Hormonal contributors. Patients with hyperandrogenic features (women with PCOS, men with high androgen sensitivity) may have more severe scalp acne. Hormonal evaluation and therapy in selected cases.
Scalp acne — acne pattern in the hair-bearing scalp
Scalp acne is the scalp manifestation of acne vulgaris. This section covers presentation and treatment.
Presentation. Papules and pustules along the frontal hairline, central scalp, and nape. Often in patients with acne-prone facial skin. Aggravated by occlusive hair products (heavy oils, pomades, certain styling products), tight headwear, and sweating.
Pathophysiology. Similar mechanism as facial acne — sebum, follicular hyperkeratinisation, Cutibacterium acnes colonisation, inflammation. Hair-care factors are important contributors.
Diagnosis. Clinical pattern. Distinction from folliculitis is sometimes needed; the two can co-exist.
First-line treatment. Topical retinoid solution (tretinoin or adapalene) applied 3–5 nights weekly. Salicylic acid 2% shampoo 2–3 times weekly. Antibacterial shampoo (chlorhexidine) in selected cases. Reduce occlusive hair products. Address sweating and headwear factors.
Second-line therapy. Oral antibiotic (doxycycline, minocycline) for 8–12 weeks in moderate-to-severe disease. Oral isotretinoin in severe nodular scalp acne unresponsive to other therapy.
Hormonal therapy in selected female patients. Combined oral contraceptives, spironolactone for hyperandrogenic patterns; coordinated with broader hormonal acne management.
Maintenance. Continued topical retinoid; salicylic shampoo 1–2 times weekly; non-comedogenic hair-product selection; ongoing trigger management.
Common patient questions about scalp acne
"Why do I get acne on my scalp?" Same mechanisms as facial acne combined with hair-care factors. Some patients have predominantly scalp acne with minimal facial acne; others have both.
"Will hair products worsen it?" Heavy occlusive products often do. The dermatologist recommends non-comedogenic alternatives.
"Will it scar?" Mild cases usually do not. Severe nodular scalp acne can produce scarring loss; early aggressive treatment minimises.
"Can I still oil my hair?" Yes, with appropriate timing and product selection. Heavy oiling on actively inflamed scalp may worsen; lighter oils applied 1–2 hours before washing rather than overnight may be acceptable.
"Will it come back?" Possible. Maintenance therapy reduces recurrence.
Detailed counselling about scalp acne management
Scalp acne is sometimes overlooked because it is partly hidden by hair. Patients arrive after months of trying anti-dandruff shampoos for what they thought was "scalp dandruff" but is actually acne pattern.
Diagnosis distinction from folliculitis. Folliculitis is purely follicular pustules; scalp acne includes papules and comedonal-like lesions in addition. Both can coexist.
Topical retinoid use on the scalp. Tretinoin 0.025% solution or adapalene 0.1% gel applied 3–5 nights weekly. Solution penetrates hair-bearing scalp better than gel for some patients. Initial irritation common in first 2–4 weeks; titrate frequency to tolerance.
Salicylic acid shampoo. 2% in regular shampoo formulations. Used 2–3 times weekly during active phase, then once weekly maintenance. Provides exfoliation and oil control.
Antibacterial shampoo when bacterial component coexists. Chlorhexidine-based products in selected cases.
Hair-product review. Heavy occlusive products (pomades, certain hair oils, leave-in conditioners) often contribute. Switch to non-comedogenic alternatives during active phase.
Oral antibiotic therapy in moderate-to-severe disease. Doxycycline 100 mg daily or minocycline 100 mg daily for 8–12 weeks. Photosensitivity counselling for doxycycline. Drug interactions reviewed.
Oral isotretinoin in severe nodular scalp acne. Dermatologist-supervised course. Pre-prescription evaluation including pregnancy considerations in female patients.
Hormonal therapy in selected female patients. Combined oral contraceptives or spironolactone for hyperandrogenic patterns.
Maintenance. Continued retinoid (reduced to alternate or twice-weekly). Salicylic shampoo weekly. Non-comedogenic product selection. Trigger management.
Detailed counselling about sensitive scalp management
Sensitive scalp management is fundamentally about routine simplification and trigger avoidance rather than aggressive medical therapy.
Patch testing. Considered when contact allergy is suspected based on temporal pattern with specific products. Identifies allergens for indefinite avoidance.
Routine simplification. 3–4 trusted products rather than 8–10. Fragrance-free, sulphate-free formulations preferred.
New product introduction. One product at a time with 2-week observation. Patch test on inner forearm before scalp use in highly sensitive patients.
Avoidance strategies. Hot water, vigorous towel-rubbing, abrasive brushes, excessive blow-dry heat all aggravate. Lukewarm water; gentle pat-dry; soft brushes; lower heat settings.
Cold-weather adaptations. Humidifier use in winter. Gentle moisturising routine. Pre-emptive application of barrier-supportive products before extreme cold exposure.
Travel adaptations. Sensitive-scalp patients sometimes flare with hotel water, new products, or climate change. Bring own products on travel; avoid hotel shampoos in highly sensitive patients.
Stress management. Subjective scalp sensitivity often increases during stress. Stress-management strategies are supportive.
Anti-itch agents. Low-dose menthol or polidocanol topicals selectively for symptomatic relief without aggravating sensitivity.
Topical calcineurin inhibitor for inflammatory component. Tacrolimus 0.1% or pimecrolimus 1% used periodically when subtle inflammation is present.
Steroid-sparing approach. Long-term topical steroid use can worsen sensitivity over time; the dermatologist limits steroid use to brief flare control rather than maintenance.
Sensitive scalp — symptomatic reactions with limited visible signs
Sensitive scalp is a clinical pattern of symptomatic reactions to products or environmental triggers with often-minimal visible signs. This section covers approach and management.
Presentation. Itching, burning, tingling, or stinging on the scalp in response to specific products, treatments, or environmental factors. Visible signs may be minimal or limited to mild redness. Patients often describe their scalp as "fragile" or "easily reactive".
Pathophysiology. Multifactorial — barrier dysfunction, contact sensitivity to specific ingredients, underlying mild eczema or psoriasis with subjective predominance, neurogenic inflammation, sometimes rosacea-related scalp involvement.
Diagnosis. Detailed history of triggers and reactions. Patch testing for suspected contact allergy. Examination for subtle signs of underlying eczema or psoriasis. Sometimes scalp biopsy in unclear cases.
First-line management. Routine simplification — fewer products, fragrance-free, sulphate-free formulations, mild cleansing, gentle styling. Identify and avoid specific triggers. Barrier support with appropriate moisturising routine.
Adjunct therapy. Topical calcineurin inhibitors for sensitive areas (avoid steroid use long-term in this group as it can worsen sensitivity). Anti-itch agents (low-dose menthol, polidocanol) selectively. Stress management.
Common contact allergens. Fragrance, paraphenylenediamine (PPD) in dyes, methylisothiazolinone (MI) preservatives, formaldehyde-releasers, propylene glycol, certain surfactants. Patch testing identifies specific allergens.
Maintenance. Long-term simple routine. New products introduced one at a time with 2-week observation. Avoidance of identified triggers indefinitely. Periodic re-evaluation if sensitivity worsens.
Common patient questions about sensitive scalp
"Why is my scalp so reactive?" Multifactorial. Sometimes can be attributed to specific allergens; sometimes broader barrier dysfunction; sometimes underlying eczema with subjective dominance.
"Will it ever get better?" Stabilises with consistent simple routine and trigger avoidance in most patients. Some patients have persistently reactive scalps that require ongoing care.
"Can I switch shampoos?" New products are introduced one at a time with 2-week observation. Many patients do best with a single trusted shampoo over years.
"Are scalp scrubs safe for sensitive scalp?" Generally avoided in actively sensitive patients. Stable patients may tolerate occasional gentle scrubs.
"Can I dye my hair?" Patch testing first. PPD-free formulations preferred. Pure natural henna is generally acceptable.
Detailed sensitive-scalp evaluation framework
The sensitive-scalp consultation often takes longer than other scalp consultations because the diagnosis is largely subjective and exclusion of underlying inflammatory conditions is important.
History detail. Onset, triggers, specific symptoms (burning vs itching vs tingling), product correlations, environmental correlations, stress correlations, hormonal correlations, previous treatment responses.
Examination detail. Whole-scalp inspection looking for subtle inflammatory signs that may indicate underlying eczema or psoriasis or rosacea-related involvement. Trichoscopy for peri-follicular signs.
Patch testing. Standard series plus expanded hair-product series in patients with strong product correlation. Reading at 48 and 96 hours; sometimes delayed reading at 7 days for some allergens.
Sometimes scalp biopsy. In patients with significant subjective symptoms and refractory presentation, small punch biopsy can identify subclinical inflammation, early scarring features, or unusual conditions.
Routine simplification approach. The most useful intervention in many sensitive-scalp patients is reducing the number of products. Patients sometimes use 8–12 products on the scalp; reducing to 3–4 trusted simple products often produces substantial improvement.
Product replacement strategy. Replace unknown products with simple fragrance-free sulphate-free formulations. Reintroduce specific products one at a time with 2-week observation. Maintain a written list of tolerated products.
Environmental adjustments. Lukewarm water rather than hot. Pat dry rather than vigorous towelling. Soft brushes; gentle styling. Lower heat on blow-drying. Humidifier in winter.
Stress management acknowledgement. Most sensitive-scalp patients describe symptom flares during high-stress periods. The dermatologist accepts stress as a real input without imposing specific psychological intervention.
Detailed pollution-scalp interaction
Particulate matter deposition. PM2.5 and PM10 particles deposit on the scalp from air pollution. The particles include carbonaceous material, metallic compounds, and adsorbed organic chemicals. Cumulative deposition over months produces oxidative stress and mild inflammatory baseline elevation.
Microbiome disruption. Pollution-driven changes in scalp microclimate and surface chemistry can shift microbiome composition, sometimes contributing to seborrhoeic dermatitis flares.
Direct irritation. Sensitive-scalp patients experience direct symptomatic flares on high-pollution days.
Mitigation strategies. Daily gentle cleansing on high-pollution days to reduce deposition. Antioxidant scalp serums (vitamin C, vitamin E formulations) in selected sensitive-scalp patients. Outdoor head covering in extreme conditions where culturally and practically feasible.
Treatment of underlying conditions. The foundation. Stable underlying scalp conditions are less reactive to environmental triggers including pollution.
Mask-and-headcover use during outdoor activity. Reduces direct deposition. Particularly useful during peak pollution events.
Indoor air quality consideration. HEPA air filtration in homes and offices reduces indoor PM2.5 levels. Patients with severe pollution-driven flares sometimes benefit measurably.
Suitability for scalp-treatment approaches
Suitability assessment matches patient and protocol after diagnosis. Some patients are suitable for the full ladder; some need a subset; some need to defer treatment or be routed elsewhere.
Suitable for foundational topical therapy
Almost every diagnosed scalp-condition patient is suitable for foundational topical therapy. Patients with intact scalp barrier or barrier-supportive routine, ability to apply topicals or use medicated shampoos, and willingness to commit to the prescribed schedule.
Suitable for oral antifungal therapy
Tinea capitis patients (children primarily). Adults with confirmed tinea capitis and absence of contraindications. Malassezia folliculitis patients with moderate-to-severe disease unresponsive to topical alone. Liver function review before extended oral antifungal courses; routine monitoring during therapy in some cases.
Suitable for oral antibiotic therapy
Bacterial folliculitis with extensive or refractory disease. Scalp acne with moderate-to-severe disease. Scarring inflammatory conditions (folliculitis decalvans) under specialist supervision. Drug-allergy review before prescription.
Suitable for systemic immunomodulatory therapy
Severe extensive psoriasis. Severe extensive atopic dermatitis. Specific scarring inflammatory conditions. Specialist supervision. Pre-prescription evaluation including infection screening, vaccination review, lab baseline.
Suitable for phototherapy
Selected scalp psoriasis or scalp eczema patients. Excimer laser for localised scalp psoriasis; UVB for broader involvement. Equipment availability and patient practicality factor in.
Suitable for topical immunomodulators
Sensitive areas in scalp eczema or seborrhoeic dermatitis. Steroid-sparing maintenance. Generally well tolerated; rare contact reactions.
Patients better routed elsewhere or deferred
Patients with severe scarring alopecia in active inflammatory phase — anti-inflammatory therapy first; transplant evaluation only when stable for 1–2 years.
Pregnant patients with mild stable scalp condition — maintain pregnancy-safe simple routine; defer aggressive therapy until postpartum.
Patients on isotretinoin currently — coordinate scalp care with the prescribing dermatologist; some scalp conditions resolve as the course completes.
Patients with significant immunosuppression and atypical scalp presentations — evaluate for opportunistic infections; coordinated care with prescribing specialists.
Patients with unrealistic expectations of one-time resolution for chronic conditions — expectation alignment first; treatment after alignment.
Patients with severe or unusual presentations not fitting common patterns — consider scalp biopsy and broader workup before committing to long-term therapy.
Special populations
Children. Tinea capitis is the most common scalp condition needing dermatology evaluation in children. Treat aggressively; family screening. Adolescent seborrhoeic dermatitis is common and responds to age-appropriate antifungal shampoos plus mild adjunct therapy.
Pregnancy. Most topical therapies are pregnancy-acceptable in selective use. Many oral therapies are avoided. The dermatologist confirms pregnancy-safe protocols.
Breastfeeding. Most topical therapies are acceptable; many oral therapies are also acceptable. Coordinated dermatology and obstetric care.
Elderly. All modalities possible with attention to comorbidities, medication interactions, and skin fragility. Slower healing; gentle technique selection.
Patients with diabetes. Increased risk of fungal and bacterial infections. Aggressive treatment of even mild conditions warranted. Glucose control review.
Patients on multiple medications. Drug-interaction review. Coordination with prescribing physicians.
Patients with mental health conditions. Some scalp conditions are aggravated by stress; supportive care includes mental-health acknowledgement and coordination when appropriate.
The scalp-treatment ladder summarised
Treatment is graded across multiple modalities. The dermatologist enters the ladder at the appropriate rung based on diagnosis, severity, patient factors, and prior response.
Rung 1 — foundational scalp care. Gentle non-stripping cleansing. Sulphate-free shampoos in sensitive scalps. Lukewarm water. Pat dry rather than vigorous towelling. Avoidance of harsh chemical processes during active flares. Reasonable styling habits.
Rung 2 — medicated shampoos. Antifungal shampoos (ketoconazole 2%, ciclopirox, zinc pyrithione, selenium sulphide). Tar-based shampoos. Salicylic acid descaling shampoos. Antibacterial shampoos. Used at appropriate frequencies and contact times for the specific condition.
Rung 3 — topical corticosteroid solutions, foams, gels, or sprays. Mid-to-high potency for flare control over 2–4 weeks; lower potency for maintenance.
Rung 4 — topical calcineurin inhibitors. Tacrolimus 0.1% or pimecrolimus 1%. Steroid-sparing maintenance. Sensitive areas.
Rung 5 — vitamin D analogues. Calcipotriol topical solution. Often combined with topical steroid for psoriasis.
Rung 6 — keratolytics. Salicylic acid topical for descaling thick plaques. Urea-containing products in selected cases.
Rung 7 — topical antibiotics. Mupirocin, fusidic acid, clindamycin for bacterial folliculitis.
Rung 8 — topical retinoids. Tretinoin or adapalene for scalp acne and selected pigmentation/inflammatory conditions.
Rung 9 — oral antifungals. Terbinafine or itraconazole for confirmed fungal infection. Liver-function review.
Rung 10 — oral antibiotics. Doxycycline, minocycline, cephalexin for moderate-to-severe folliculitis or scalp acne.
Rung 11 — oral immunomodulators. Methotrexate, cyclosporine, apremilast, biologics for severe psoriasis, severe atopic dermatitis, or specific scarring inflammatory conditions. Specialist supervision.
Rung 12 — phototherapy. Excimer laser, UVB for selected scalp psoriasis or scalp eczema patients.
Rung 13 — coordinated hair-loss treatment. When scalp condition coexists with hair-loss pattern, integrated care with hair-regrowth therapy.
What is NOT routinely on the DDC ladder
Aggressive scalp peels at high concentrations without specific indication. Risk-benefit does not justify routine use.
Ozone scalp therapy as marketed by some clinics. Evidence base is weak; not part of evidence-based practice.
"Detox" scalp protocols promising removal of toxins. The skin does not require detoxification through external products.
Mesotherapy with proprietary unverified cocktails. If components and evidence cannot be specified, the treatment is not part of evidence-based practice.
Single-product "scalp wellness" transformation solutions marketed online. Patients are counselled toward evidence-based options.
Common scalp conditions at a glance
A grid showing the common scalp conditions side by side with their typical features and first-line therapy.
Conditions sometimes overlap. The dermatologist disentangles at consultation and treats each contributor in coordinated sequence rather than chasing the most visible symptom alone.
The 13-rung scalp-treatment ladder
A visual ladder showing the rungs from foundational scalp care at the bottom to coordinated hair-loss therapy at the top. The dermatologist enters the appropriate rungs based on diagnosis.
Most patients use a combination of rungs 1–3 for foundational care plus condition-specific rungs above. Severe disease combines multiple rungs simultaneously.
What happens at each in-clinic session
Patients want to know what to expect at each type of session. This section walks through the experience.
Initial consultation. 30–45 minutes. Detailed history, scalp examination, dermoscopy as indicated, KOH preparation if fungal infection suspected, photographs, treatment plan, prescriptions, follow-up scheduling. The longest single visit; the foundation of the plan.
4-week review. 15–25 minutes. Response assessment, photograph comparison, side-effect screening, plan adjustments. Most acute conditions show improvement at this stage; chronic conditions are entering controlled-flare phase.
8–12 week review. 15–25 minutes. Continued response assessment. Transition planning toward maintenance phase. Photograph comparison.
KOH preparation in clinic. Skin scrapings on a slide; potassium hydroxide 10–20% applied; microscopic examination 5–15 minutes after slide preparation. Same-visit result.
Bacterial culture collection. Pus or exudate collected on swab; sent to laboratory; report in 2–5 days. Sensitivity profile guides antibiotic selection.
Patch testing. Allergens applied to back skin in patches at one visit; readings at 48 hours and 96 hours over subsequent visits. Result interpretation at the final reading visit.
Scalp biopsy. Local anaesthesia; small punch removal; suture placement; healing in 7–14 days. Histopathology report in 7–14 days.
Phototherapy session. 5–15 minutes per session. Excimer laser to localised plaques or UVB to broader scalp. 2–3 sessions weekly during active phase. Course typically 8–16 sessions for response.
Annual review. 20–30 minutes. Comprehensive reassessment. Long-term plan adjustments. Photograph comparison.
Pre-session preparation
Wash hair 24 hours before consultation if possible — examination is best on clean dry hair. Same-day hair-washing also acceptable but earlier washing reveals more.
Bring product list — current shampoo, conditioner, styling products, any medicated shampoos used. Photographs of products if helpful.
Bring medication list including over-the-counter and supplements.
Note recent scalp procedures, chemical processing, or hair-care changes.
Bring current trichoscopy or dermatologist reports if previously evaluated elsewhere.
What happens with results
KOH same-visit result. Positive findings change treatment immediately to antifungal therapy. Negative findings rule out fungal infection.
Bacterial culture results 2–5 days later. Sensitivity-guided antibiotic if culture positive. Negative culture supports non-bacterial differential.
Patch testing results at the final reading visit. Specific allergens for avoidance documented in writing.
Biopsy results 7–14 days. Diagnosis confirmed or refined; treatment adjusted accordingly.
The dermatologist explains all results clearly, integrates them into the treatment plan, and supports the patient through any necessary plan adjustments.
Long-term maintenance after the active phase
Many scalp conditions are chronic with recurring flares. Maintenance therapy reduces flare frequency and severity. This section covers maintenance strategies by condition.
Seborrhoeic dermatitis maintenance. Antifungal shampoo once or twice weekly indefinitely. Some patients use a rotation of two anti-yeast shampoos to prevent tolerance. Reactive escalation during flares — increased frequency or addition of mid-potency steroid for 1–2 weeks.
Scalp psoriasis maintenance. Often a combination of weekly antifungal shampoo, periodic topical steroid or vitamin D analogue, and ongoing trigger management. Individualised based on disease activity. Some patients maintain stable scalp with minimal active therapy; others need ongoing regimens.
Scalp eczema maintenance. Gentle cleansing routine indefinitely. Topical calcineurin inhibitor 2–3 times weekly for steroid-sparing maintenance. Trigger avoidance. Reactive flare management with brief topical steroid courses.
Tinea capitis maintenance. Usually does not recur after appropriate treatment. Family screening at the time of treatment plus environmental decontamination (combs, hats, pillows) supports clearance. Monitoring for recurrence in households with ongoing pet or schoolyard exposure.
Folliculitis maintenance. Trigger management is the primary maintenance strategy. Antibacterial shampoo periodic use in patients with recurrent bacterial folliculitis. Antifungal shampoo for Malassezia folliculitis maintenance.
Scalp acne maintenance. Continued topical retinoid; salicylic shampoo 1–2 times weekly; non-comedogenic product selection; ongoing trigger management.
Sensitive scalp maintenance. Long-term simple routine. Periodic re-evaluation. New products introduced one at a time with 2-week observation.
Common maintenance pitfalls
Stopping medicated shampoos because the scalp looks normal. Most common avoidable cause of recurrence in seborrhoeic dermatitis. The dermatologist reinforces ongoing maintenance at every follow-up.
Returning to harsh styling routines after stabilisation. Re-flares are common.
Adding new products without dermatologist review in sensitive-scalp patients. Trigger introductions worsen previously stable scalp.
Letting follow-up lapse. Annual review identifies subtle drift before significant flare.
Self-adjusting medications without dermatologist guidance. Patients sometimes increase or decrease topical steroid use beyond the prescribed pattern; supervised adjustment produces better long-term outcomes.
Cadence variations across patient groups
Mild seborrhoeic patients. Antifungal shampoo once weekly maintenance. Annual review.
Moderate-to-severe seborrhoeic patients. Twice-weekly antifungal plus reactive steroid or calcineurin inhibitor. Quarterly review during early stabilisation, then annual.
Stable scalp psoriasis patients. Quarterly review. Periodic topical regimen as prescribed. Coordination with body-psoriasis dermatology if applicable.
Stable scalp eczema patients. Quarterly review during early stabilisation, then annual. Trigger reinforcement at each visit.
Post-tinea-capitis children. Single follow-up at completion of treatment; longer-term review only if recurrence.
Recurrent folliculitis patients. Periodic review with trigger reassessment; antimicrobial maintenance regimen.
Sensitive-scalp patients. Annual review with product-routine reinforcement. More frequent if symptoms drift.
Safety considerations across scalp-treatment modalities
Scalp dermatology is generally safe in qualified hands. Adverse events are uncommon and almost always manageable. Diagnosis-first practice prevents inappropriate therapy in atypical presentations.
Topical antifungal safety. Generally well tolerated. Mild scalp dryness or irritation in some patients. Rare contact sensitivity. Pregnancy use of ketoconazole 2% shampoo generally considered safe with limited absorption.
Topical corticosteroid safety. Mid-potency for limited courses is generally well tolerated. Long-term high-potency use can produce scalp atrophy, telangiectasia, and rare systemic absorption effects. The dermatologist tapers and supervises long-term steroid use carefully. Patients are taught not to use topical steroids indefinitely without supervision.
Topical calcineurin inhibitor safety. Generally well tolerated. Initial burning sensation common in first 1–2 weeks; usually settles. Pregnancy use selective.
Vitamin D analogue safety. Generally well tolerated. Local irritation in some patients. Pregnancy use limited.
Salicylic acid safety. Topical 2–6% generally well tolerated. Higher concentrations can cause burning and barrier disruption.
Topical retinoid safety. Initial irritation and dryness common. Photosensitivity. Pregnancy contraindicated for tretinoin and adapalene.
Oral antifungal safety. Liver enzyme elevations occasional with terbinafine and itraconazole; routine baseline and periodic monitoring during extended courses. Drug interactions important — reviewed before prescription.
Oral antibiotic safety. Standard antibiotic side-effect profiles. Photosensitivity with doxycycline. Drug interactions reviewed.
Systemic immunomodulator safety. Significant safety profile including infection susceptibility. Pre-prescription screening (TB, hepatitis), vaccination review, lab monitoring, specialist supervision.
Phototherapy safety. Skin cancer risk with cumulative exposure. Eye protection during sessions. Long-term supervision.
Specific complications and management
Topical steroid-induced scalp atrophy. Reduce frequency, transition to calcineurin inhibitor, supervised tapering.
Contact dermatitis from medicated topicals. Discontinue offending agent; alternative therapy.
Oral medication side effects. Specific to the agent; clinic communication and management.
Infection during treatment. Bacterial superinfection of scalp eczema or psoriasis: targeted antibiotic. Herpes reactivation rare; antiviral if needed.
Treatment failure or progression despite appropriate therapy. Re-evaluation, biopsy, specialist referral.
Documentation and consent
Every prescription documented with consent process for systemic medications.
Side-effect reports documented and management documented.
Plan adjustments documented.
Patients encouraged to contact the clinic with any concerning symptom rather than waiting for the next scheduled visit.
Comparison tables for decision-making
Patients often want to compare conditions or modalities side by side. This section provides three comparison tables.
Seborrhoeic dermatitis vs scalp psoriasis
| Aspect | Seborrhoeic dermatitis | Scalp psoriasis |
|---|---|---|
| Scaling | Greasy yellowish | Thick silver |
| Borders | Poorly defined | Well defined |
| Distribution | Often diffuse central | Often plaques |
| Body involvement | Sometimes facial sebaceous areas | Often elsewhere on body |
| First-line | Antifungal shampoo + steroid | Steroid + vitamin D + tar |
| Maintenance | Antifungal shampoo weekly | Reactive topicals |
Tinea capitis vs scalp psoriasis vs alopecia areata
| Aspect | Tinea capitis | Scalp psoriasis | Alopecia areata |
|---|---|---|---|
| Scaling | Patchy with broken hairs | Thick silver | Smooth, no scaling |
| Hair loss | Patchy in affected area | Diffuse mild from inflammation | Sharply demarcated bald patches |
| Age group | Children primarily | Any age | Any age |
| Treatment | Oral antifungal 4–8 weeks | Topical steroid + vit D | Intralesional steroid |
| Confirmatory test | KOH + culture | Clinical / dermoscopy | Clinical / dermoscopy |
Topical vs oral therapy decision
| Aspect | Topical-only | Topical + oral |
|---|---|---|
| Severity | Mild-to-moderate | Moderate-to-severe |
| Distribution | Localised | Extensive or unresponsive |
| Confirmed fungal | Sometimes adequate | Tinea capitis always needs oral |
| Setting | Self-applied at home | Combined home and prescribed oral |
| Monitoring | Clinical follow-up | Lab monitoring for some agents |
| Best for | Common conditions; first-line | Severe, refractory, or specific oral indications |
Common myths about scalp conditions
Scalp conditions are surrounded by myths. The dermatologist addresses these at consultation.
Myth: dandruff is caused by poor hygiene. Reality: dandruff and seborrhoeic dermatitis are not hygiene problems; they involve microbiome interactions and immune-system factors. Reasonable cleansing is part of management but is not the cause of the condition.
Myth: cutting hair shorter resolves scalp conditions. Reality: hair length does not cause scalp conditions. Some patients prefer shorter hair during active treatment for product-application convenience but trimming alone does not treat any condition.
Myth: only adults get scalp conditions. Reality: children develop tinea capitis, cradle cap, scalp eczema, and other conditions. Paediatric scalp dermatology is a substantial subspecialty.
Myth: natural shampoos are safer. Reality: many "natural" shampoos contain potential allergens (fragrance, essential oils, plant extracts). Sensitive-scalp patients sometimes do worse with "natural" formulations than with simple fragrance-free synthetic options.
Myth: psoriasis can be cured with diet alone. Reality: dietary patterns may modulate severity in some patients but do not resolve the underlying immune-mediated condition. Comprehensive medical management is the standard.
Myth: scratching helps scalp itch. Reality: scratching damages the barrier, worsens inflammation, and produces a vicious cycle. Anti-itch therapy and trigger management address the underlying cause.
Myth: oils cause dandruff. Reality: heavy occlusive oils on inflamed scalp can worsen seborrhoeic dermatitis but do not cause it. Cultural oiling routines are usually compatible with treatment when timed appropriately.
Myth: scalp problems mean hair-transplant problems. Reality: most scalp conditions do not preclude hair transplant. Active inflammatory disease should be stable for 1–2 years before transplant; otherwise transplant goes ahead with medical scalp care continued.
Myth: alcohol-based scalp solutions damage hair. Reality: most alcohol-based topicals are safe in measured use. Excessive use may dry the scalp; the dermatologist recommends appropriate vehicles for individual patients.
Myth: scalp problems are always permanent. Reality: many are chronic with manageable flares; some are transient and resolve completely with treatment. The condition determines the realistic outlook.
Additional myths and clarifications
Myth: shaving the head clears scalp conditions. Reality: hair length does not cause conditions and shaving does not treat them. Some patients prefer shorter hair during active treatment for product-application convenience but shaving alone is not therapeutic.
Myth: scalp conditions are caused by stress alone. Reality: stress is one trigger among many. The underlying condition exists independently of stress; stress can flare an existing condition but does not produce it from nothing.
Myth: certain blood types or hair types are immune to scalp conditions. Reality: blood type does not affect scalp condition susceptibility. Hair type sometimes correlates with specific patterns (CCCA in type IV–VI hair) but no hair type is immune to scalp dermatology concerns.
Myth: scalp infections can be treated by drinking specific juices or supplements. Reality: oral antifungal medication is required for confirmed fungal scalp infections. No juice or supplement provides equivalent therapy.
Myth: dandruff causes hair loss. Reality: severe scalp inflammation can produce some shedding from associated inflammation, but dandruff itself does not directly cause hair loss. Treating the inflammation often improves both scalp comfort and any associated shedding.
Myth: only people with poor hair-care habits get scalp problems. Reality: scalp conditions develop in patients with excellent hair-care routines as well. Genetic, immune, and microbiome factors are often more important than hair-care intensity.
Myth: scalp problems mean impending baldness. Reality: most scalp conditions do not cause permanent hair loss. Severe scarring conditions can; common conditions usually do not.
Myth: weather is the only trigger of seborrhoeic dermatitis. Reality: weather is one trigger; stress, illness, hormonal shifts, and medication changes also contribute. Many patients have multifactorial trigger patterns.
Myth: every scalp condition needs a special expensive shampoo. Reality: many evidence-based scalp shampoos are affordable and widely available. Generic ketoconazole 2% costs a small fraction of premium "scalp wellness" products and outperforms many of them in efficacy for the conditions where it is indicated.
Myth: scalp conditions are visible only at active flare. Reality: trichoscopy can reveal subclinical signs of chronic conditions during quiescent phases. Surveillance during stable phases can detect drift before significant flare.
Decision tree — what should happen with my scalp problem
A simple decision tree to guide pre-consultation thinking.
The decision tree is a pre-consultation orientation. Examination, dermoscopy, and selected tests at consultation refine pathway selection.
Who supervises scalp treatment at DDC
Scalp dermatology at DDC is supervised by senior dermatologists with specific training in scalp and hair conditions.
Dr Chetna Ghura — Lead Dermatologist
MBBS, MD Dermatology · DMC 2851 · 16 years
Lead reviewer for scalp dermatology protocols. Oversees diagnosis-first practice and the integration of scalp care with hair-loss management. Responsible for scalp-treatment ladder calibration and for routing decisions between dermatology and specialist referral pathways.
Dr Kashish Mahajan — Cosmetic Dermatology
MBBS, DDVL · 9 years
Oversees scalp cosmetic and supportive care including PRP and microneedling for scalp conditions, integration with broader cosmetic dermatology, and adjunct optimisation alongside medical scalp therapy.
Dr Seerat Goraya — Procedural Dermatology
MBBS, MD Dermatology · 11 years
Oversees scarring inflammatory scalp conditions and severe folliculitis. Manages cases requiring anti-inflammatory therapy, intralesional steroid protocols, and specialist coordination for biological therapy or surgical referral.
Dr Ankit Malik — Procedural Dermatology
MBBS, DDVL · 8 years
Oversees male-pattern scalp conditions including beard-area folliculitis and pseudo-folliculitis, scalp acne in men, and scalp dermatology integrated with men\u2019s grooming routines.
Dr Reena Tomar — Cosmetic Dermatology
MBBS, MD Dermatology · 13 years
Oversees female-specific scalp conditions including hormonal scalp acne and post-procedural scalp care. Coordinates with gynaecology and endocrinology for hormonal-driven scalp patterns.
How this content is reviewed and maintained
Medical content at DDC is governed by a defined editorial process.
Annual review cycle. Each medical page is reviewed at least once a year by a named dermatologist. Updates dated; next review date published.
Update triggers between reviews. New evidence, regulatory changes, modality additions or removals, patient queries.
Author and reviewer identification. Named dermatologists with publicly verifiable medical registration numbers.
Conflict-of-interest disclosure. DDC does not accept payment for endorsement of specific products or device platforms.
Patient-facing accuracy. The clinic prioritises accuracy over marketing optimism. Recurrence-and-maintenance reality, side-effect realities, and biological timelines are stated explicitly.
Diagnosis-first policy reference. The clinic\u2019s diagnosis-first approach to scalp dermatology is documented internal protocol with consistent staff training and consistent application across consultations.
Quick-reference scalp-treatment glossary — 30 terms
A glossary of 30 terms commonly encountered during scalp-treatment consultation.
- Antifungal shampoo
- Shampoo containing antifungal agents (ketoconazole, ciclopirox, zinc pyrithione, selenium sulphide) used to treat seborrhoeic dermatitis and other yeast-driven conditions.
- Atopic dermatitis
- Chronic inflammatory skin condition with itchy patches; scalp eczema is its scalp manifestation.
- Bacterial folliculitis
- Infection of hair follicles by bacteria, commonly Staphylococcus aureus.
- Calcineurin inhibitor
- Class of immune-modulating topical agents (tacrolimus, pimecrolimus) used as steroid-sparing maintenance.
- Calcipotriol
- Vitamin D analogue used topically for psoriasis.
- Ciclopirox
- Broad-spectrum antifungal in shampoo and other formulations.
- Cradle cap
- Infantile seborrhoeic dermatitis; usually self-limiting.
- Dandruff
- Mild non-inflammatory scalp flaking; the milder end of the seborrhoeic spectrum.
- Dermoscopy
- Magnified skin examination using polarised light at 10x; valuable for scalp diagnosis.
- Eczema
- Inflammatory dermatitis presenting as itchy patches; many subtypes.
- Excimer laser
- Targeted UVB phototherapy device used for localised psoriasis or eczema.
- Folliculitis
- Inflammation of hair follicles; bacterial, fungal, or irritation-related.
- Folliculitis decalvans
- Severe scarring inflammatory folliculitis with progressive follicular destruction.
- Itraconazole
- Oral antifungal used for some fungal scalp infections.
- Kerion
- Severe inflammatory tinea capitis with boggy painful patches.
- Ketoconazole
- Antifungal agent commonly used in 2% shampoo for seborrhoeic dermatitis.
- KOH preparation
- Microscopic test for fungal hyphae using potassium hydroxide.
- Malassezia
- Commensal yeasts on the scalp; overgrowth contributes to seborrhoeic dermatitis and folliculitis.
- Microbiome
- The community of microorganisms (bacteria, fungi) living on the scalp; balance contributes to scalp health.
- Phototherapy
- Therapeutic light exposure (UVB, excimer) for selected scalp conditions.
- Psoriasis
- Immune-mediated chronic inflammatory skin condition with thick scaling plaques.
- Salicylic acid
- Keratolytic agent used in shampoo and topical solutions for descaling.
- Scalp acne
- Acne pattern in hair-bearing scalp.
- Seborrhoeic dermatitis
- Common chronic inflammatory scalp condition associated with Malassezia yeast.
- Sensitive scalp
- Symptomatic scalp reactions to triggers with often-minimal visible signs.
- Tar shampoo
- Coal-tar-based shampoo used in psoriasis and seborrhoeic dermatitis.
- Terbinafine
- Oral antifungal used for tinea capitis and other dermatophyte infections.
- Tinea capitis
- Fungal scalp infection caused by dermatophytes; primarily children.
- Topical corticosteroid
- Anti-inflammatory topical used in many scalp conditions.
- Trichodynia
- Painful scalp without visible inflammation.
Pricing for scalp treatment
Scalp treatment at DDC starts from ₹1,999 for a dermatologist consultation. Per-modality pricing depends on diagnosis and treatment ladder.
Consultation fee. Covers detailed history, scalp examination, dermoscopy, KOH preparation as indicated, photographs, written treatment plan, follow-up review.
Topical prescriptions. Modest monthly pharmaceutical cost; medicated shampoos are the largest ongoing item for chronic-condition patients.
Oral antifungal therapy. Moderate cost over the 4–8 week course; generic terbinafine is widely available.
Oral antibiotic therapy. Modest cost over the 7–14 day course.
Systemic immunomodulator therapy. Higher cost; biologics are highest. Specialist coordination.
Phototherapy sessions. Per-session cost; courses of 8–16 sessions accumulate.
Biopsy. Modest cost including procedure plus histopathology.
Lab tests. Per-test cost; varies by panel.
Why per-procedure pricing
DDC uses per-procedure pricing rather than packages. Patients pay for what is needed; chronic-condition patients have low ongoing costs after initial stabilisation.
Cost ranges
Common conditions managed topically. Lower total annual cost. Consultation plus monthly pharmaceutical costs plus annual review.
Severe or systemic-therapy-requiring conditions. Higher total annual cost. Specialist supervision and lab monitoring add costs.
Tinea capitis treatment course. Moderate one-time cost; usually no ongoing maintenance after clearance.
Insurance and tax
Some scalp conditions may be partially covered by health insurance — particularly conditions producing significant medical impact. Cosmetic-priority scalp care is generally not covered. The patient checks with their insurer. GST applies. Detailed invoices issued.
Downloadable references
Patients on active scalp-treatment receive take-home references.
- Diagnosis card — your specific condition and matched plan
- Topical application guide — shampoo contact times and frequencies
- Oral medication card — dosing and side-effect monitoring where applicable
- Trigger-management card — your individual triggers
- Maintenance schedule — month-by-month plan
- Routine simplification guide for sensitive-scalp patients
- Glossary one-pager
Patients refer to these in the first months as the routine becomes established.
Lifestyle factors that affect scalp-treatment outcomes
Lifestyle inputs affect both treatment response and ongoing scalp health.
Sleep. Adequate sleep supports immune-mediated condition stability and barrier recovery.
Stress. Chronic stress flares seborrhoeic dermatitis, psoriasis, and sensitive-scalp symptoms. Stress management is supportive but not primary.
Diet. Adequate balanced nutrition supports general scalp health. Specific deficiencies (zinc, fatty acids, B-complex) can affect scalp; correction supports recovery.
Smoking. Aggravates psoriasis severity. Cessation supports better outcomes.
Alcohol. Excessive alcohol can flare seborrhoeic dermatitis and psoriasis in some patients.
Exercise. Regular exercise supports general health. Sweat-related folliculitis is managed by prompt washing after sessions.
Hair-care practices during active scalp treatment
Avoid tight hairstyles producing chronic traction during active flares.
Avoid harsh chemical processes (bleaching, relaxers, intense colour processing) on actively inflamed scalps.
Use gentle non-stripping cleansing routines suited to the condition.
Continue cultural hair-oiling routines if desired but adjust timing — apply 1–2 hours before washing rather than overnight in seborrhoeic patients to avoid prolonged occlusion.
Avoid sharing combs, brushes, hats, and pillows during active fungal infections.
Replace pillowcases regularly during active inflammatory or infectious flares.
Discuss any new hair-care interest with dermatologist — some new products help, others interfere.
Cultural and lifestyle factors specific to Indian patients
Hair oil traditions. Coconut, almond, amla, bhringraj oils have hydration benefits. Adjust timing in seborrhoeic patients to allow medical shampoo contact time.
Henna and plant-based colourings. Pure natural henna is generally fine. Black henna with PPD can trigger contact dermatitis.
Religious headcovering. Compatible with treatment; tightness should be moderate. Daily aeration supports scalp health.
Climate effects. North Indian seasonal extremes affect scalp. Winter dryness flares dermatitis; pre-emptive moisturising routine helps. Summer heat increases sweating-related folliculitis; hygiene routines adjust.
Pollution exposure. Daily gentle cleansing, antioxidant scalp serums, and treating underlying conditions reduces pollution impact.
Wedding and event timing. The dermatologist plans treatment timelines around major events realistically; severe conditions need stable maintenance phase before significant events.
Indian-scalp specific deeper considerations
Several Indian-population-specific factors interact with scalp dermatology in ways that deserve detailed attention.
Hard-water scalp effects
Many areas in India have hard water with high mineral content. Hard water leaves residue on hair and scalp; combined with shampoo it can produce a film that contributes to dullness, scalp dryness, and inflammatory flare in susceptible patients. Patients with persistent unexplained scalp irritation despite appropriate medical therapy benefit from evaluating their water supply; clarifying shampoos used periodically may help; in extreme cases, water filtration considered.
Oil-massage cultural practices
The cultural practice of warm-oil scalp massage is deeply rooted in Indian tradition. The dermatologist respects this practice and accommodates it in treatment plans. Some patients use oil massage as a generations-old family ritual rather than for hair-care benefit alone. The medical-care plan integrates oil-massage routines without judgement, with timing adjustments when relevant. Coconut oil, almond oil, sesame oil, and herbal oils each have their tradition; the dermatologist asks rather than assumes.
Ayurvedic and herbal scalp products
Patients sometimes use ayurvedic preparations alongside medical therapy. The dermatologist welcomes patient choice when products are from reputable sources and not interfering with prescribed treatment. Some preparations contain undisclosed ingredients including steroids; the dermatologist asks to review unknown formulations. Patients with reactions after starting an ayurvedic product are evaluated for contact sensitivity.
Religious headcovering and scalp care
Patients wearing turbans, religious caps, hijabs, or other headcoverings have specific considerations — friction at attachment points, occlusion under headcovering, sweat retention in warm weather. The dermatologist accommodates the practice. Daily aeration of the scalp where culturally feasible supports scalp health. Brief uncovered periods at home or before bed allow microclimate to normalise.
Frequency-of-washing variability
Some patients wash hair daily; others wash once weekly; cultural and personal preferences vary widely. The dermatologist accommodates the patient\u2019s washing pattern in treatment design. Daily washing patients may use medicated shampoos as the daily shampoo; weekly washing patients use medicated shampoos as the weekly shampoo with non-medicated rinses or dry-shampoo techniques between.
Climate-driven seasonal patterns
Delhi\u2019s seasonal cycle produces predictable scalp-condition patterns. Winter dryness flares dermatitis. Spring dust storms produce sensitive-scalp reactions. Summer heat and humidity increase folliculitis and sebum-driven conditions. Monsoon humidity favours fungal proliferation. Post-monsoon air pollution peaks. Autumn allows brief respite. The dermatologist plans seasonal adjustments at quarterly review.
Pollution-driven scalp inflammation specifics
PM2.5 and other pollutants deposit on the scalp and hair. Contributions to oxidative stress, inflammatory baseline elevation, and direct irritation are documented. Daily gentle cleansing on high-pollution days, antioxidant-supportive scalp serums in selected patients, and outdoor head covering in extreme conditions reduce impact. Treatment of underlying conditions remains the foundation; pollution mitigation is supportive.
Family-shared bathroom considerations
Many Indian households have shared bathrooms with shared towels, combs, and grooming items. Tinea capitis transmission risk in shared environments is real. The dermatologist provides specific guidance on personal-item separation during active fungal infection. Family-screening of children when an index case is identified.
Wedding-season scalp planning
Indian wedding-season patterns produce predictable scalp-condition concerns. Patients preparing for personal weddings or for attending many family weddings benefit from advance scalp-condition stabilisation. The dermatologist plans 3–6 months ahead of major events for chronic conditions; acute conditions can be addressed in shorter windows.
What the evidence base says about scalp treatment
Scalp treatments have substantial evidence bases of varying strength.
Antifungal shampoos for seborrhoeic dermatitis. Strong evidence over decades. Multiple randomised trials show efficacy.
Topical corticosteroids for psoriasis and eczema. Strong long-established evidence.
Vitamin D analogues for psoriasis. Strong evidence; often combined with steroid for synergy.
Topical calcineurin inhibitors. Strong evidence in atopic dermatitis; used selectively in scalp eczema and seborrhoeic dermatitis.
Oral antifungal for tinea capitis. Strong evidence; topical-only is consistently inadequate.
Oral antibiotics for folliculitis and scalp acne. Substantial evidence in moderate-to-severe disease.
Systemic therapy for severe psoriasis or eczema. Strong evidence; specialist supervision.
Phototherapy. Substantial evidence for selected conditions.
Patient-reported satisfaction with comprehensive scalp dermatology programmes. Generally high when expectations are realistic and maintenance is accepted.
Patient-reported outcomes versus measured outcomes
For scalp dermatology, both objective measurement (visible scaling, redness, plaque thickness via standardised photographs and trichoscopy) and patient-reported outcomes (itch reduction, comfort, confidence) matter. Both endpoints inform clinical decision-making.
Where treatment falls short of expectations sometimes encountered. It does not eliminate underlying chronic conditions; it controls flares. It does not produce one-time resolution in chronic conditions. It does not address all subjective scalp discomfort in some sensitive patients.
What patients can reasonably expect from comprehensive care. Stabilisation of chronic conditions; reduction in flare frequency and severity; resolution of acute conditions where appropriate; supportive long-term relationship for ongoing care.
Detail on evidence levels for specific scalp interventions
Ketoconazole 2% shampoo. Multiple controlled trials demonstrating efficacy in seborrhoeic dermatitis with consistent reduction in scaling, erythema, and itch. The shampoo retains activity at the scalp for several hours after rinsing because the active ingredient binds to keratin. Long-term safety profile well established.
Ciclopirox shampoo. Comparable efficacy to ketoconazole in head-to-head trials. Useful in patients with ketoconazole intolerance or for rotation to prevent yeast tolerance.
Zinc pyrithione. Long-established over-the-counter active. Evidence supports efficacy in mild seborrhoeic dermatitis and dandruff. Often used as the maintenance shampoo for stable patients.
Selenium sulphide. Older agent with established efficacy; sometimes irritating; used selectively.
Tar-based shampoos. Long-established efficacy in psoriasis and seborrhoeic dermatitis. Some patients dislike the smell or staining; reformulations have improved cosmetic acceptability.
Topical calcipotriol. Strong evidence in psoriasis. Calcipotriol-betamethasone combination products have particularly good evidence and convenient dosing.
Topical corticosteroids. Long-established efficacy across inflammatory scalp conditions. Solution and foam vehicles preferred for scalp application convenience.
Topical calcineurin inhibitors. Strong evidence in atopic dermatitis. Off-label scalp use has good clinical experience particularly for steroid-sparing maintenance.
Salicylic acid. Long-established keratolytic efficacy. Useful in psoriasis with thick scaling and in seborrhoeic dermatitis with crusting.
Oral terbinafine for tinea capitis. Strong evidence; first-line for most dermatophyte species. Paediatric weight-adjusted dosing well characterised.
Oral griseofulvin for tinea capitis. Older first-line agent; effective for some species where terbinafine activity is limited. Longer treatment duration.
Oral itraconazole and fluconazole for selected fungal scalp infections. Used in patients with terbinafine intolerance or specific organism profiles.
Phototherapy for psoriasis. Strong evidence for body psoriasis; selected scalp applications. Excimer laser for localised plaques; broadband or narrowband UVB for extensive disease.
Biologic therapy in severe psoriasis. Strong evidence including in psoriasis with significant scalp involvement. Specialist supervision.
Dupilumab and other biologics for severe atopic dermatitis. Strong evidence including reduction in scalp involvement. Specialist supervision.
The scalp-treatment patient journey at DDC
A first-time scalp-treatment patient at DDC follows a typical journey.
First contact. Phone, WhatsApp, walk-in. Receptionist offers consultation slot.
Consultation. 30–45 minutes. Detailed history, scalp examination, dermoscopy, KOH preparation if indicated, photographs. Written diagnosis and plan.
Lab and culture results review. 1–2 weeks later if tests ordered. Plan finalised.
Active phase 4–12 weeks. Topical and oral as prescribed. Periodic clinic review.
4-week review. Response assessment, plan adjustments.
8–12 week review. Transition planning toward maintenance.
Maintenance phase. Quarterly review during early stabilisation, then annual.
Long-term relationship. Patients return for years for ongoing maintenance and any new concerns.
Final note. The relationship between patient and dermatologist often extends across decades. Patients return for ongoing scalp care, related dermatology concerns, and family-member referrals. The clinic supports this longitudinal model. Patient autonomy fully respected throughout.
How the journey differs by condition
Seborrhoeic dermatitis journey. Patient presents with itchy flaky greasy scalp. Diagnosis confirmed clinically. Antifungal shampoo plus brief topical steroid course initiated. Improvement at 2–4 weeks. Transition to weekly antifungal maintenance. Annual review. Occasional flares managed reactively. The patient settles into a sustainable routine that produces stable scalp for years.
Scalp psoriasis journey. Patient presents with raised plaques. Diagnosis confirmed clinically and dermoscopically. Topical steroid plus vitamin D analogue initiated; salicylic acid for descaling thick plaques. Improvement at 4–8 weeks. Transition to maintenance with reactive topicals. Stress and seasonal triggers managed. Some patients require ongoing systemic therapy for sustained control.
Scalp eczema journey. Patient presents with dry itchy patches. Atopic background confirmed. Gentle non-stripping cleansing routine plus topical steroid foam during flares plus topical calcineurin inhibitor maintenance initiated. Improvement at 3–6 weeks. Trigger avoidance reinforced. Annual review with patient feedback on routine sustainability.
Tinea capitis journey. Child presents with patchy hair loss and scaling. KOH preparation positive. Oral terbinafine started at weight-adjusted dose for 6 weeks. Family screening — siblings often need treatment. Selenium sulphide shampoo as adjunct. Re-evaluation at 6–8 weeks; KOH and culture for clearance confirmation. Hair regrows over 3–9 months after fungal clearance.
Folliculitis journey. Patient presents with follicular pustules. Cultures sent if extensive or refractory. Topical antibiotic plus trigger management initiated. Most cases resolve at 2–4 weeks. Recurrent folliculitis patients receive ongoing trigger-management plan and periodic antibacterial shampoo.
Scalp acne journey. Patient presents with hairline papules. Topical retinoid solution plus salicylic shampoo plus product-recommendation review initiated. Improvement at 6–10 weeks. Maintenance with retinoid reduced to alternate nights plus weekly salicylic shampoo. Hair-product selection coordinated.
Sensitive scalp journey. Patient presents with subjective scalp reactions. Patch testing sometimes performed. Routine simplified to 3–4 trusted products. Triggers identified and avoided. Stabilisation over 8–12 weeks. Long-term simple routine maintained.
Multi-condition presentations. Many patients have overlapping conditions — seborrhoeic dermatitis plus scalp acne, or scalp psoriasis plus folliculitis, or eczema with secondary infection. The dermatologist treats each condition in coordinated sequence. Plan reviews at 4-week intervals during active phase to prevent treatment of one condition aggravating another.
Patient adherence patterns observed at the clinic
Patients with uncomplicated single conditions usually maintain compliance well. Twice-weekly antifungal shampoo for seborrhoeic dermatitis is easy to integrate into existing washing routines.
Patients with multi-product regimens may struggle with compliance during busy periods. The dermatologist simplifies regimens where possible and provides written reminders.
Patients on oral antifungal courses for tinea capitis sometimes forget doses; the dermatologist provides specific timing guidance and supports reminder strategies.
Patients who experience initial product-related side effects (mild irritation from medicated shampoo) sometimes stop prematurely. The dermatologist forewarns at consultation and provides specific guidance on managing transient side effects.
Patients in stable maintenance phase sometimes drift away from routine over months or years. Annual review identifies drift and recalibrates.
Cost considerations across the journey
Common conditions managed topically. Lower total annual cost. Most patients spend a modest amount on prescribed shampoos and topicals plus consultation fees.
Severe conditions requiring oral therapy. Moderate to higher cost during active phase. Generic medications keep costs reasonable for many patients.
Severe conditions requiring biological therapy. Higher cost; specialist supervision; sometimes partial insurance coverage.
Tinea capitis treatment course. Moderate one-time cost over 6–8 weeks; usually no ongoing costs after clearance.
Recurrent conditions. Cumulative annual cost depends on flare frequency and severity. Maintenance investment usually outperforms repeated acute-flare treatment costs.
Insurance coverage varies. Some scalp conditions producing significant medical impact may be partially covered. Cosmetic-priority care is generally not covered. The patient checks with their insurer.
Common questions patients ask during the consultation
Certain questions come up repeatedly. The dermatologist answers with the kind of nuance that comes up in person.
"Will this come back?"
Most chronic scalp conditions recur without maintenance. The good news is that maintenance is usually simple — a medicated shampoo once or twice weekly often suffices.
"How fast will I see results?"
Acute conditions: 2–4 weeks. Chronic conditions: 4–8 weeks for visible control. Tinea capitis: full clearance over 6–8 weeks of oral antifungal.
"Can I just use over-the-counter shampoos?"
For mild dandruff sometimes yes. For moderate-to-severe conditions, prescription-grade therapy outperforms OTC options.
"Will my hair fall out from the condition?"
Active inflammation can produce shedding that recovers when the condition is treated. Permanent loss is uncommon except in severe scarring conditions.
"Can I oil my hair during treatment?"
Usually yes, with timing adjustments to allow medicated shampoo contact time first.
"What about the products I have at home?"
The dermatologist reviews them. Some are compatible; some should be paused; some may be contributing to the problem.
"Will my children get this?"
Depends on the condition. Atopic and psoriatic conditions have genetic component; tinea capitis can be transmitted.
"Are there permanent solutions?"
For acute conditions yes (tinea capitis, mild folliculitis). For chronic conditions, sustained control is the realistic goal rather than permanent resolution.
"Should I change my diet?"
Specific deficiencies should be corrected. Routine elimination diets are not generally helpful unless individual triggers are identified.
"What if treatment doesn\u2019t work?"
Re-evaluation. Confirm diagnosis (sometimes biopsy). Adjust regimen. Consider specialist coordination for refractory cases.
Detailed expectations across response trajectory
Patients tracking their own response month by month benefit from understanding specific milestones. This section walks through expected response across the active and maintenance phases.
Week 1–2 — initial settling
Topical regimen started; medicated shampoo on prescribed schedule. Some patients notice mild scalp dryness or initial irritation that settles. Patients with significant inflammation may notice itch reduction within days. Patients on oral antifungal for tinea capitis may not see external change yet but the treatment is acting at the follicle level.
Week 3–4 — first measurable response
Inflammation visibly reducing. Scaling reducing. Itch substantially better in most compliant patients. Photographic comparison with baseline often shows clear improvement. Patients with stubborn or atypical disease may not respond yet; re-evaluation considered if no response.
Week 5–8 — continued improvement
Acute conditions often largely controlled at this point. Chronic conditions stabilising into manageable steady state. Some patients begin transition to maintenance phase. Side-effect screening at clinic review.
Week 9–12 — formal mid-phase review
Photographic comparison documents response. Trichoscopy at this stage often shows resolved peri-follicular inflammation. Plan adjustment — most patients reduce active-treatment intensity and transition to maintenance.
Months 3–6 — maintenance phase begins
Routine becomes habitual. Once-or-twice-weekly medicated shampoo replaces daily intensive use. Reactive flare management for occasional disturbances.
Months 6–12 — settled maintenance
Most patients have stable scalp at this point. Annual review confirms continued control. Plan adjustments rare unless life circumstances change.
Year 2 onward
Settled long-term care relationship. Annual review. Reactive flare management. Plan evolves with life stage, hormonal phases, and emerging conditions.
Realistic outcomes by condition
Mild seborrhoeic dermatitis. Excellent control with weekly antifungal shampoo maintenance.
Moderate-to-severe seborrhoeic dermatitis. Good control with twice-weekly antifungal plus reactive steroid use; flares occasional but manageable.
Mild scalp psoriasis. Good control with topical regimens; some flares related to stress and seasonal triggers.
Moderate-to-severe scalp psoriasis. Variable control depending on severity; some patients require systemic therapy for sustained control.
Scalp eczema. Good control with gentle routine and reactive flare therapy. Flares related to triggers identified and avoided.
Tinea capitis. Full clearance over 6–8 weeks of oral antifungal in most patients. Recurrence uncommon.
Folliculitis. Most acute cases resolve fully. Recurrent folliculitis requires ongoing trigger management.
Scalp acne. Good control with topical retinoid regimen plus periodic salicylic acid shampoo. Severe cases may need oral therapy.
Sensitive scalp. Stabilises with consistent simple routine and trigger avoidance. Some patients have persistently reactive scalp requiring ongoing care.
Scalp concerns frequently confused
Patients sometimes describe one condition that turns out to be another. The dermatologist clarifies at consultation.
Dandruff vs seborrhoeic dermatitis
Spectrum, not separate conditions. Mild flaking without redness is dandruff; redness with greasy scaling is seborrhoeic dermatitis.
Seborrhoeic dermatitis vs scalp psoriasis
Greasy yellowish vs silver scaling; poorly defined vs well-defined; often body involvement in psoriasis.
Scalp eczema vs sensitive scalp
Visible dermatitis vs subjective symptoms with minimal signs.
Tinea capitis vs alopecia areata
Scaling with broken hairs vs smooth bald patches with characteristic dermoscopy.
Folliculitis vs scalp acne
Pure follicular pustules vs papules-and-comedones pattern.
Sensitive scalp vs early lichen planopilaris
Subjective with minimal signs vs subtle peri-follicular inflammation; trichoscopy distinguishes.
Pityriasis amiantacea vs lichen planopilaris
Both can produce hairline scaling. Trichoscopy and biopsy distinguish.
Trichodynia vs neuralgia
Painful scalp without inflammation may be trichodynia or neurological in origin.
Hair shedding from scalp condition vs primary hair-loss pathology
Dermoscopy and pull test distinguish; coordinated care addresses both when present. Patients sometimes have both — a chronic scalp condition contributing to shedding plus an underlying AGA tendency. The dermatologist treats both in coordinated sequence.
Scalp odour from condition vs environmental sources
Treatment of underlying condition resolves condition-related odour. Some odour is from external sources (smoke exposure, certain occupational environments, particular hair products) rather than from the condition itself; environmental adjustment addresses these.
Scalp pain from neuralgia vs trichodynia
Trichodynia is painful scalp without visible inflammation, sometimes associated with telogen effluvium or sensitive-scalp baseline. Neuralgia is nerve-related pain following specific nerve distributions. Different management; the dermatologist distinguishes at consultation and refers to neurology when needed.
Diffuse scalp redness from rosacea-related involvement vs sensitive scalp
Some patients with rosacea have scalp involvement producing chronic redness and burning. Anti-rosacea topical therapy may help. Sensitive-scalp without rosacea is managed differently. Clinical pattern distinguishes.
Scalp condition vs adverse reaction to ongoing medication
Some medications produce scalp side effects (oral isotretinoin can cause dermatitis-like scalp; certain antihypertensives can flare psoriasis). Medication review at consultation identifies these.
Discoid lupus vs alopecia areata
Both can produce patchy scalp involvement. Discoid lupus shows characteristic scarring, atrophy, and pigmentary changes. Specialist care for confirmed lupus.
Lichen planopilaris vs sensitive scalp
Early lichen planopilaris can present with subjective burning before visible scarring becomes evident. Trichoscopy and biopsy distinguish in selected cases.
Combining scalp treatment with other dermatology care
Many patients have related concerns. This section covers common combinations.
Scalp treatment + hair regrowth therapy
Coordinated care when both conditions coexist. Scalp condition treated first stabilises the foundation for hair-regrowth therapy.
Scalp treatment + facial dermatitis
Seborrhoeic dermatitis and atopic dermatitis often involve both scalp and face. Coordinated topical and systemic plans.
Scalp treatment + facial acne management
Scalp acne and facial acne often coexist. Coordinated topical and oral acne therapy.
Scalp treatment + general dermatology surveillance
Patients on long-term scalp care benefit from broader dermatology surveillance for skin cancer and other concerns.
Scalp treatment + paediatric coordination
Children with scalp conditions sometimes need coordinated paediatric dermatology and family screening.
Scalp treatment + hormonal evaluation
Hormonal contributors to scalp acne and seborrhoeic dermatitis warrant coordinated endocrine evaluation in selected cases.
Scalp treatment + nutrition consultation
Identified deficiencies addressed through dietitian or supplementation.
Scalp treatment + mental health support
Stress contributors to chronic scalp conditions sometimes warrant coordinated mental-health support.
Scalp treatment + specialist coordination
Severe scarring inflammatory conditions, severe psoriasis with body involvement, or severe atopic dermatitis benefit from coordinated dermatology and specialist care.
Scalp treatment + family screening
Tinea capitis cases warrant family-member screening and treatment of any contact-source pet.
Scalp treatment + cosmetic dermatology integration
Patients seeking facial cosmetic care often have related scalp concerns that benefit from coordinated evaluation. Anti-ageing patients with scalp psoriasis flares from chemical processing benefit from coordinated planning. Brightening-pathway patients with sensitive scalp need product coordination. The dermatologist looks at the broader picture rather than treating each concern in isolation.
Scalp treatment + post-procedural scalp care
Patients having undergone hair transplant, scalp procedures elsewhere, or major chemical processing benefit from scalp-care plans during recovery. The dermatologist coordinates with the procedure provider when relevant.
Scalp treatment + travel and lifestyle planning
Patients planning major travel during active scalp treatment benefit from specific guidance on continuing therapy across travel, managing scalp care in different climates, and timing of any planned procedural work.
Scalp treatment + aesthetic dermatology integration
Patients on long-term scalp care often develop broader cosmetic dermatology needs over time. The clinic supports the longitudinal patient relationship across multiple concerns.
Special-population considerations
Some patient groups need protocol adjustments.
Children
Tinea capitis is the most common scalp condition needing dermatology evaluation in children. Aggressive treatment with oral antifungal. Family screening.
Adolescents
Seborrhoeic dermatitis and scalp acne are common. Age-appropriate medicated shampoo plus mild adjunct therapy.
Pregnancy
Most pregnancy-compatible options available with selective use. Confirm pregnancy-safe protocols.
Breastfeeding
Most topical options acceptable. Many oral options also acceptable. Coordinated dermatology and obstetric care.
Perimenopausal women
Hormonal scalp acne and seborrhoeic flares are common. Hormonal evaluation in selected cases.
Patients with diabetes
Increased risk of fungal and bacterial scalp infections. Aggressive treatment of even mild conditions.
Patients with immune compromise
Atypical and refractory scalp conditions. Specialist coordination.
Patients on multiple medications
Drug-interaction review. Coordination with prescribing physicians.
Patients with mental health conditions
Stress-driven flares are common. Supportive coordinated care. Some patients benefit from coordinated care with mental-health professionals when stress is a major driver of recurrent flares; the dermatologist makes referrals when relevant and supports the broader patient situation.
Elderly
All modalities possible with attention to skin fragility and comorbidities. Slower healing; gentle technique selection. Polypharmacy considerations — many elderly patients are on multiple medications with potential interactions; the dermatologist coordinates with the primary care physician. Manual dexterity considerations — patients with arthritis or other dexterity limitations may need simpler topical regimens; family-member or caregiver support sometimes helpful for application.
Patients with dermatologic comorbidities
Patients with multiple skin conditions across body and scalp benefit from coordinated dermatology care. Atopic dermatitis with scalp involvement; psoriasis with scalp involvement; rosacea with scalp involvement in some patients. Single-clinic continuity supports consistent treatment approach across all affected sites.
Patients with auto-immune conditions
Lupus erythematosus with scalp involvement (discoid lupus). Specialist care including immunology coordination. Anti-malarial therapy as core treatment.
Dermatomyositis with scalp involvement. Specialist care.
Pemphigus and pemphigoid with scalp involvement. Specialist care; immunosuppressive therapy.
Patients with limited financial resources
Many evidence-based scalp treatments are affordable. Generic ketoconazole shampoo, generic topical steroids, generic oral antifungals all provide cost-effective care. The dermatologist customises plans to patient financial circumstances. Patients are encouraged to discuss cost openly so plans match what is sustainable.
Patients in remote settings
Patients far from major dermatology centres benefit from teleconsultation between in-person visits. Photograph-based response tracking; regimen adjustments by dermatologist; in-person visits for procedures or initial diagnostic evaluation. Modern teleconsultation supports continuity of care across distance.
Honest answers before you book
Common questions about scalp treatment — what conditions are covered, how diagnosis works, treatment options for each condition, maintenance, and how scalp care fits with broader hair-and-scalp dermatology.
What is "scalp treatment"?
Is scalp treatment the same as hair regrowth treatment?
Do I need a consultation or can I just get a salon scalp treatment?
What is seborrhoeic dermatitis?
Is dandruff the same as seborrhoeic dermatitis?
What is scalp psoriasis?
How is scalp eczema treated?
What is tinea capitis?
What is folliculitis?
Can the scalp get acne?
What does "sensitive scalp" mean?
How is scalp diagnosis done?
How long does treatment take?
Will my scalp condition come back?
Is scalp treatment safe during pregnancy?
Can I treat my scalp at home with natural remedies?
How does pollution affect my scalp?
Should I stop using oils on my scalp?
Can I dye my hair during treatment?
What about scalp scrubs and exfoliation?
Will my child grow out of cradle cap?
How does seborrhoeic dermatitis differ from psoriasis?
Can stress trigger scalp flares?
Does diet affect the scalp?
What if my scalp condition does not improve with treatment?
Should I use medicated shampoos every day?
Can scalp problems cause permanent hair loss?
How is the assessment done?
How much does treatment cost?
Can scalp treatment be combined with hair regrowth therapy?
Is there a special haircare routine for scalp conditions?
Will my pillow or comb spread the condition?
What should I do during a flare?
Are there any foods to avoid?
How is this content reviewed?
Public reference layer — scalp treatment
This page draws on dermatology references for educational accuracy. It does not reproduce clinical guidelines verbatim and does not constitute personal medical advice.
- 1Borda LJ, Wikramanayake TC. Seborrheic dermatitis and dandruff: a comprehensive review. Journal of Clinical and Investigative Dermatology. 2015;3(2).
- 2Naldi L, Diphoorn J. Seborrhoeic dermatitis of the scalp. BMJ Clinical Evidence. 2015;2015:1713.
- 3Gupta AK, Bluhm R, Cooper EA, Summerbell RC, Batra R. Seborrheic dermatitis. Dermatologic Clinics. 2003;21(3):401–412.
- 4Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clinics in Dermatology. 2013;31(4):343–351.
- 5Papp KA, Berth-Jones J, Kragballe K, et al. Scalp psoriasis: a review of current topical treatment options. Journal of the European Academy of Dermatology and Venereology. 2007;21(9):1151–1160.
- 6Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology. 2009 (multi-section guidelines).
- 7Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunological Reviews. 2011;242(1):233–246.
- 8Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. Journal of the American Academy of Dermatology. 2014 (multi-section guidelines).
- 9Gupta AK, Summerbell RC. Tinea capitis. Medical Mycology. 2000;38(4):255–287.
- 10Fuller LC, Barton RC, Mohd Mustapa MF, Proudfoot LE, Punjabi SP, Higgins EM. British Association of Dermatologists\u2019 guidelines for the management of tinea capitis. British Journal of Dermatology. 2014;171(3):454–463.
- 11Goldust M, Ranjkesh MR, Amirinia M, Golforoushan F, Rezaee E, Rezazadeh Saatlou MA. Sertaconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis. Journal of Dermatological Treatment. 2013;24(5):369–371.
- 12Suh KS, Kang JS, Baek JW, et al. Sebopsoriasis: a clinical and dermoscopic perspective. Annals of Dermatology. 2012;24(4):505–509.
- 13Bharti S, Sharma R, Gupta R. Pityriasis amiantacea: a clinico-aetiological review. International Journal of Dermatology. 2008.
- 14Bunagan MJ, Banka N, Shapiro J. Retrospective review of folliculitis decalvans in 23 patients with course and treatment analysis of long-standing cases. Journal of Cutaneous Medicine and Surgery. 2015;19(1):45–49.
- 15Misery L. Sensitive skin: pathophysiological hypothesis and concept. Sensitive Skin Syndrome. 2006.
- 16Saint-Jean M, Khammari A, Jasson F, Nguyen JM, Dréno B. Different cutaneous innate immunity profiles in acne patients with and without atrophic scars. European Journal of Dermatology. 2016;26(1):68–74. Discusses scalp acne pathophysiology overlap.
- 17American Academy of Dermatology. Patient resources on scalp conditions. Available at: aad.org/public
- 18Indian Association of Dermatologists, Venereologists and Leprologists. Position statements on scalp dermatology and tinea capitis management.
- 19DDC clinical governance: All treatment content reviewed by named dermatologist. Medical registration numbers publicly verifiable. Offline clinical approvals maintained per DDC internal governance protocol.
Get a scalp-dermatology assessment before starting any plan
The next step is a dermatologist consultation that diagnoses the specific scalp condition and proposes a treatment plan with realistic timelines and explicit maintenance discussion.
- Diagnosis-first plan with dermoscopy
- Realistic 4–12 week active phase framing
- Maintenance honesty for chronic conditions
- Indian-scalp calibration throughout
- Starting from ₹1,999*
Book your scalp consultation
By submitting this form, you agree to be contacted by our team. This form does not create a doctor-patient relationship. Many scalp conditions are chronic with recurring flares requiring ongoing maintenance. Outcomes vary by condition, severity, and compliance.